EX-13

Management’s Discussion and Analysis of Results of Operations and Financial Condition

Organization and Business Segments

DESCRIPTION OF THE COMPANY AND BUSINESS SEGMENTS

Johnson & Johnson and its subsidiaries (the “Company”) have approximately 119,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.

The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a broad range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. The Medical Devices and Diagnostics segment includes a broad range of products used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction and spinal care products; Ethicon’s wound care and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products and Vision Care’s disposable contact lenses.

The Company’s structure is based upon the principle of decentralized management. The Executive Committee of Johnson & Johnson is the principal management group responsible for the operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments. Each subsidiary within the business segments is, with some exceptions, managed by citizens of the country where it is located.

In all of its product lines, the Company competes with companies both large and small, located throughout the world. Competition is strong in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and improved products is important to the Company’s success in all areas of its business. This also includes protecting the Company’s portfolio of intellectual property. The competitive environment requires substantial investments in continuing research and multiple sales forces. In addition, the development and maintenance of customer acceptance of the Company’s consumer products involves significant expenditures for advertising and promotion.

MANAGEMENT’S OBJECTIVES

A primary objective of the Company is to achieve superior levels of capital efficient profitable growth. To accomplish this, the Company’s management operates the business consistent with certain strategic principles that have proven successful over time. To this end, the Company participates in growth areas in human health care and is committed to attaining leadership positions in these growth segments through the development of innovative products and services. New products introduced within the past five years accounted for approximately 30% of 2007 sales. In 2007, $7.7 billion, or 12.6% of sales was invested in research and development, an increase of $0.6 billion over 2006. This increase reflects management’s commitment to the importance of on-going development of new and differentiated products and services to sustain long-term growth.

With more than 250 operating companies located in 57 countries, the Company views its principle of decentralized management as an asset and fundamental to the success of a broadly based business. It also fosters an entrepreneurial spirit, combining the extensive resources of a large organization with the ability to react quickly to local market changes and challenges.

The Company is committed to developing global business leaders who can drive growth objectives. Businesses are managed for the long term in order to sustain leadership positions and achieve growth that provides an enduring source of value to our shareholders.

Unifying the management team and the Company’s dedicated employees in achieving these objectives is Our Credo. Our Credo provides a common set of values and serves as a constant reminder of the Company’s responsibilities to its customers, employees, communities and shareholders. The Company believes that these basic principles, along with its overall mission of improving the quality of life for people everywhere, will enable Johnson & Johnson to continue to be among the leaders in the health care industry.

Results of Operations

ANALYSIS OF CONSOLIDATED SALES

In 2007, worldwide sales increased 14.6% to $61.1 billion, compared to increases of 5.6% in 2006 and 6.7% in 2005. These sales increases consisted of the following:


Sales increase due to:	2007			2006		2005
Volume		10.1	%		3.8		5.4
Price		1.4			1.5		0.6
Currency		3.1			0.3		0.7

Total		14.6	%		5.6		6.7

Sales by U.S. companies were $32.4 billion in 2007, $29.8 billion in 2006 and $28.4 billion in 2005. This represents an increase of 9.0% in 2007, 4.9% in 2006 and 2.2% in 2005. Sales by international companies were $28.7 billion in 2007, $23.5 billion in 2006 and $22.1 billion in 2005. This represents an increase of 21.7% in 2007, 6.4% in 2006 and 13.1% in 2005.


36				JOHNSON & JOHNSON 2007 ANNUAL REPORT

The five-year compound annual growth rates for worldwide, U.S. and international sales were 11.0%, 7.6% and 15.7%, respectively. The ten-year compound annual growth rates for worldwide, U.S. and international sales were 10.5%, 10.6% and 10.3%, respectively.

All international geographic regions experienced sales growth during 2007, consisting of 22.4% in Europe, 32.2% in the Western Hemisphere (excluding the U.S.) and 15.3% in the Asia-Pacific, Africa regions. These sales increases include the impact of currency fluctuations between the U.S. dollar and foreign currencies, which had positive impacts of 9.2% in Europe, 6.7% in the Western Hemisphere (excluding the U.S.) and 3.5% in the Asia-Pacific, Africa region.

The acquisition of Pfizer Inc.’s Consumer Healthcare business, net of the related divestitures, increased both total sales growth and operational growth by 7.4%.

In 2007, 2006 and 2005, the Company did not have a customer that represented 10% or more of total revenues.

Analysis of Sales by Business Segments

CONSUMER SEGMENT

Consumer segment sales in 2007 were $14.5 billion, an increase of 48.3%, over 2006 with 44.2% of this change due to operational growth and the remaining 4.1% due to positive currency fluctuations. U.S. Consumer segment sales were $6.4 billion, an increase of 40.1%. International sales were $8.1 billion, an increase of 55.5%, with 47.8% as a result of operations and 7.7% due to currency fluctuations over 2006.

The acquisition of Pfizer Inc.’s Consumer Healthcare business, net of the related divestitures, increased both total sales growth and operational growth for the total Consumer segment by 40.3%.

The Over-the-Counter (OTC) Pharmaceuticals and Nutritionals franchise sales were $5.1 billion, an increase of 87.5% from 2006. This was attributable to new products from acquisitions, as well as strong sales growth achieved by analgesics and SPLENDA^® products. The positive impact on OTC Pharmaceuticals and Nutritionals total sales growth due to newly acquired brands from Pfizer Inc. was 80.0% for the fiscal year 2007.

In 2007, the Company announced a voluntary withdrawal of certain infant cough and cold products from the market. When used as directed, these medicines have been generally recognized as safe and effective. However, an assessment of available data on the use of pediatric cough and cold medicines has identified rare instances of misuse leading to overdose, particularly in infants under two years of age. As well, these products, along with children’s cough and cold products generally, were the subject of a recent U.S. Food and Drug Administration (FDA) Nonprescription Drug Advisory Committee hearing, which recommended to the FDA certain changes in the marketing and

Major Consumer Franchise Sales*:


							% Change
(Dollars in Millions)	2007		2006		2005		‘07 vs.‘06			‘06 vs.‘05
OTC Pharmaceuticals & Nutritionals	$	5,142		2,742		2,678		87.5	%		2.4
Skin Care		3,051		2,633		2,401		15.9			9.7
Baby Care		1,982		1,740		1,561		13.9			11.5
Women’s Health		1,806		1,666		1,568		8.4			6.3
Oral Care		1,488		406		319		266.5			27.3
Other		1,024		587		569		74.4			3.2


Total	$	14,493		9,774		9,096		48.3	%		7.5


*		Prior year amounts have been reclassified to conform with current presentation.


MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION				37

sale of such products. These actions are not expected to have a significant impact on sales for the OTC Pharmaceuticals and Nutritionals franchise.

The Skin Care franchise sales in 2007 were $3.1 billion, representing an increase of 15.9% over 2006. The increase was primarily due to sales growth in the suncare, CLEAN & CLEAR^®, AVEENO^® and NEUTROGENA^® product lines, as well as new products related to acquisitions. The positive impact on Skin Care total sales growth due to newly acquired brands from Pfizer Inc. was 5.7% for the fiscal year 2007.

The Baby Care franchise sales grew by 13.9% to $2.0 billion in 2007. This strong growth was led by the success of the cleanser, haircare, lotion and cream and powder product lines. An additional contributor to the growth were the new products related to acquisitions. The positive impact on Baby Care total sales growth due to newly acquired brands from Pfizer Inc. and divestitures related to the acquisition was 1.8% for the fiscal year 2007.

The Women’s Health franchise sales grew by 8.4% to $1.8 billion in 2007. This growth was primarily due to newly acquired brands from Pfizer Inc. The positive impact on Women’s Health total sales growth due to newly acquired brands from Pfizer Inc. was 4.8% for the fiscal year 2007.

The Oral Care franchise sales grew by 266.5% to $1.5 billion in 2007. This strong sales growth was attributable to new products from acquisitions and newly launched products, such as LISTERINE^® mouthwashes and dissolvable whitening strips. The positive impact on Oral Care total sales growth due to newly acquired brands from Pfizer Inc. and divestitures related to the acquisition was 276.6%.

Consumer segment sales in 2006 were $9.8 billion, an increase of 7.5%, over 2005 with operational growth accounting for 6.4% of the total growth and 1.1% due to positive currency fluctuations. U.S. Consumer segment sales were $4.6 billion, an increase of 3.8%. International sales were $5.2 billion, an increase of 10.9%, with 8.7% as a result of operations and 2.2% due to currency fluctuations over 2005.

PHARMACEUTICAL SEGMENT

Pharmaceutical segment sales in 2007 were $24.9 billion, an increase of 6.9% over 2006, with 4.3% of this change due to operational growth and the remaining 2.6% increase related to the positive impact of currency fluctuations. U.S. Pharmaceutical segment sales were $15.6 billion, an increase of 3.4%. International Pharmaceutical segment sales were $9.3 billion, an increase of 13.3%, which included 5.9% of operational growth and 7.4% related to the positive impact of currency fluctuations.

The Antipsychotics franchise achieved sales of $4.7 billion in 2007, an increase of 12.3% over prior year. The Antipsychotics franchise includes RISPERDAL^® oral (risperidone), a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients, RISPERDAL^® CONSTA^® (risperidone) a long acting injectable and INVEGA™ (paliperdone) Extended-Release tablets for the treatment of schizophrenia. Sales growth was positively impacted by the continued global success of RISPERDAL^® CONSTA^®. The patent for the RISPERDAL^® compound expired in the U.S. and most major markets outside the U.S. in 2007. In March 2007, the FDA granted pediatric exclusivity for RISPERDAL^®, which extends the marketing exclusivity in the U.S. for RISPERDAL^® oral to the end of June 2008. In 2007, U.S. sales of RISPERDAL^® oral were $2.2 billion. Loss of market exclusivity for RISPERDAL^® oral is likely to result in a significant reduction in sales in the U.S.

REMICADE^® (infliximab), a biologic approved for the treatment of Crohn’s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis and use in the treatment of rheumatoid arthritis, achieved sales of $3.3 billion in 2007, with growth of 10.4% over prior year. Growth was driven by increased demand due to expanded indications and overall market growth. During 2007, REMICADE^® received approval from the European Commission for pediatric Crohn’s disease indications. REMICADE^® is competing in a market which is experiencing increased competition due to new entrants and the expansion of indications for existing competitors.

PROCRIT^® (Epoetin alfa) and EPREX^® (Epoetin alfa) had combined sales of $2.9 billion in 2007, a decline of 9.3% compared to prior year. The decline was primarily due to the declining markets for Erythropoiesis Stimulating Agents (ESAs). Earlier in the year The Centers for Medicare and Medicaid issued a National Coverage Determination, which significantly limits the reimbursement of ESAs in oncology in the U.S. Epoetin alfa products in the U.S. were subject to a label change, which may negatively impact future sales. The label for Epoetin alfa products is also under review in jurisdictions outside the U.S.

Major Pharmaceutical Product Revenues*:


							% Change
(Dollars in Millions)	2007		2006		2005		‘07 vs. ‘06			‘06 vs. ‘05
Antipsychotics	$	4,697		4,183		3,552		12.3	%		17.8
REMICADE^® (infliximab)		3,327		3,013		2,535		10.4			18.9
PROCRIT^®/EPREX^® (Epoetin alfa)		2,885		3,180		3,324		(9.3	)		(4.3	)
TOPAMAX^® (topiramate)		2,453		2,027		1,680		21.0			20.7
LEVAQUIN^® /FLOXIN^® (levofloxacin/ofloxacin)		1,646		1,530		1,492		7.6			2.5
ACIPHEX^®/PARIET^® (rabeprazole sodium)		1,357		1,239		1,169		9.5			6.0
DURAGESIC^® /Fentanyl Transdermal (fentanyl transdermal system)		1,164		1,295		1,585		(10.1	)		(18.3	)
CONCERTA^® (methylphenidate HCI)		1,028		930		774		10.5			20.2
Hormonal Contraceptives		925		1,016		1,136		(9.0	)		(10.6	)
Other		5,384		4,854		5,075		10.9			(4.4	)


Total	$	24,866		23,267		22,322		6.9	%		4.2



*		Prior year amounts have been reclassified to conform with current presentation.


38				JOHNSON & JOHNSON 2007 ANNUAL REPORT

TOPAMAX^® (topiramate), which has been approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines, achieved $2.5 billion in sales in 2007, an increase of 21.0% over prior year. The major contributor to the growth was the continued success in the migraine category. The patent for TOPAMAX^® (topiramate) in the U.S. will expire in September 2008. The Company is on target to file for the pediatric extension with the FDA, which if obtained, would grant market exclusivity in the U.S. until March 2009. In 2007, U.S. sales of TOPAMAX^® were $2.0 billion. The expiration of a product patent or loss of market exclusivity is likely to result in a significant reduction in sales.

LEVAQUIN^® (levofloxacin) and FLOXIN^® (ofloxacin) achieved combined sales of $1.6 billion in 2007, representing growth of 7.6% over the prior year. This was primarily due to favorable market growth partially offset by increased competitive pressure. In March 2007 the FDA granted pediatric exclusivity in the U.S. for LEVAQUIN^®, which will extend the marketing exclusivity by six months to June 2011.

ACIPHEX^®/PARIET^® (rabeprazole sodium), a proton pump inhibitor co-marketed with Eisai Co. Ltd., achieved sales of $1.4 billion in 2007, an increase of 9.5% as compared to prior year. Growth in the U.S. was due to overall market growth. Growth outside the U.S. was due to market growth partially offset by increased competition in certain regions.

DURAGESIC^®/Fentanyl Transdermal (fentanyl transdermal system) sales declined to $1.2 billion in 2007, a reduction of 10.1% from 2006. This decline was the result of the impact of generic competition in the U.S. and major international markets. Generic competition in the U.S. began in January 2005.

CONCERTA^® (methylphenidate HCI), a product for the treatment of attention deficit hyperactivity disorder, achieved sales of $1.0 billion in 2007, representing an increase of 10.5% over 2006. Although the original CONCERTA^® patent expired in 2004, the FDA has not approved any generic version that is substitutable for CONCERTA^®. Two parties have filed Abbreviated New Drug Applications (ANDAs) for generic versions of CONCERTA^®, which are pending and may be approved at any time.

The hormonal contraceptive franchise sales declined to $0.9 billion in 2007, a reduction of 9.0% from 2006. ORTHO EVRA^® (norelgestromin/ethinyl estradiol), the first contraceptive patch approved by the FDA, experienced a significant decline in sales as a result of labeling changes and negative media coverage concerning product safety. The sales decline was also a result of continued generic competition in oral contraceptives.

In 2007, Other Pharmaceutical sales were $5.4 billion, representing a growth of 10.9% over prior year. The biggest contributor to the increase was VELCADE^®, a product for the treatment of multiple myeloma.

In the fiscal fourth quarter of 2007, the Company recorded a special pre-tax, non-cash charge of $678 million for the write-down of the intangible asset related to NATRECOR^® (nesiritide), a product for the treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. This charge results from revised estimates of future cash flows from this product primarily due to a recent decline in NATRECOR^® sales trends. The remaining unamortized intangible value associated with NATRECOR^® was $200 million at the end of 2007. The Company believes that NATRECOR^® is an important clinical option for the treatment of acutely decompensated heart failure and the product will continue to be marketed by Scios Inc., a subsidiary of the Company.

During 2007, the Company launched INVEGA™ (paliperidone) Extended-Release Tablets, in both the U.S. and Europe. Additionally, in 2007 the Company launched the antibacterial, DORIBAX™ (doripenem for injection) in the U.S. and the antiretroviral, PREZISTA™ (darunavir), in Europe. The Company submitted five new molecular entities for approval: paliperidone palmitate for schizophrenia in the U.S., ustekinumab, or CNTO 1275, for psoriasis in both the U.S. and Europe, dapoxetine for premature ejaculation in several countries in Europe, antibacterial ceftobiprole in the U.S. and Europe and anti-HIV medication, TMC 125 in the U.S. and Europe. TMC 125 was approved by the U.S. FDA in January 2008 and will be marketed as INTELENCE™ (etravirine).

In response to the challenges facing the Pharmaceutical segment the Company announced a restructuring initiative in 2007. See Note 22 for additional information regarding the restructuring.

Pharmaceutical segment sales in 2006 were $23.2 billion, an increase of 4.2% over 2005, with 3.9% of this change due to operational growth and the remaining 0.3% increase related to the positive impact of currency. U.S. Pharmaceutical segment sales were $15.1 billion, an increase of 4.2%. International Pharmaceutical segment sales were $8.1 billion, an increase of 4.2%, which included 3.4% of operational growth and 0.8% related to the positive impact of currency.

MEDICAL DEVICES AND DIAGNOSTICS SEGMENT

The Medical Devices and Diagnostics segment achieved sales of $21.7 billion in 2007, representing an increase over the prior

Major Medical Devices and Diagnostics Franchise Sales:


							% Change
(Dollars in Millions)	2007		2006		2005		‘07 vs. ‘06			‘06 vs. ‘05
DEPUY^®	$	4,587		4,105		3,847		11.7	%		6.7
ETHICON ENDO-SURGERY^®		3,834		3,376		3,105		13.6			8.7
ETHICON^®		3,591		3,213		3,092		11.8			3.9
CORDIS^®		3,425		4,088		3,982		(16.2	)		2.6
LIFESCAN^®		2,373		2,074		1,909		14.4			8.6
Vision Care		2,209		1,879		1,694		17.6			10.9
ORTHO-CLINICAL DIAGNOSTICS^®		1,642		1,488		1,408		10.3			5.7
Other		75		60		59		25.0			1.7


Total	$	21,736		20,283		19,096		7.2	%		6.2


MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION				39

year of 7.2%, with operational growth of 3.9% and 3.3% due to a positive impact from currency fluctuations. U.S. sales were $10.4 billion, an increase of 3.2%. International sales were $11.3 billion, an increase of 11.1%, with 4.6% from operations and a positive currency impact of 6.5%.

The DePuy franchise achieved $4.6 billion in sales in 2007, which was an 11.7% increase over prior year. This growth was primarily due to DePuy’s orthopaedic joint reconstruction products including the hip and knee product lines. Strong performance was also achieved in Mitek’s sports medicine products.

The Ethicon Endo-Surgery franchise achieved sales of $3.8 billion in 2007, a 13.6% increase over 2006. A major contributor of growth continues to be endocutter sales, which include products used in performing bariatric procedures for the treatment of obesity, an important focus area for the franchise. Strong results were achieved with the continued success of the HARMONIC SCALPEL^®, an ultrasonic cutting and coagulating surgical device. There was also strong growth in the Advanced Sterilization Products line.

The Ethicon franchise sales grew 11.8% in 2007, achieving $3.6 billion in sales. This was a result of solid growth in the hemostasis, women’s health, biosurgicals, and the mesh product lines. There was also continued growth in suture sales.

Sales in the Cordis franchise were $3.4 billion, a decline of 16.2% over 2006. This decline reflects lower sales of the CYPHER^® Sirolimus-eluting Coronary Stent due to increased competition outside the U.S., as well as the global contraction of the drug-eluting stent market following reports of a potential risk of late stent thrombosis associated with the use of drug-eluting stents. These results were partially offset by strong performance by the Biosense Webster and the neurovascular businesses. In response to challenges facing the Cordis franchise the Company announced a restructuring initiative in 2007. See Note 22 for additional information regarding the restructuring.

On June 13, 2007, the FDA notified Cordis that all items outlined in the Warning Letters received in April and July 2004 regarding Good Manufacturing Practice regulations and Good Clinical Practice regulations have been resolved.

The LifeScan franchise achieved $2.4 billion in sales in 2007, an increase of 14.4% over 2006, reflecting the continued success of the ULTRA^® product lines. An additional contributor was the growth of the Animas business due to the launch of the 2020 insulin pump during the year.

The Vision Care franchise achieved sales of $2.2 billion in 2007, a growth rate of 17.6% over the prior year. This growth was led by the continued success of such brands as ACUVUE^® OASYS™, ACUVUE^® ADVANCE™ for ASTIGMATISM, ACUVUE^® ADVANCE™, 1-DAY ACUVUE^® MOIST™, 1-DAY ACUVUE^® DEFINE™ and 1-DAY ACUVUE^® for ASTIGMATISM.

The Ortho-Clinical Diagnostics franchise achieved $1.6 billion in sales in 2007, a 10.3% increase over 2006. This is due to the continued global growth in the Immunohematology product line, as well as the growth in the Immunodiagnostic product line and the 2007 launch of the Chagas screening assay in the U.S.

The Medical Devices and Diagnostics segment achieved sales of $20.3 billion in 2006, representing an increase over the prior year of 6.2%, with operational growth of 6.4% and a negative impact from currency of 0.2%. U.S. sales were $10.1 billion, an increase of 6.5%. International sales were $10.2 billion, an increase of 5.9%, with 6.2% from operations and a negative currency impact of 0.3%.

Analysis of Consolidated Earnings Before Provision for Taxes on Income

Consolidated earnings before provision for taxes on income decreased by $1.3 billion to $13.3 billion in 2007 as compared to the $14.6 billion earned in 2006. Lower earnings in 2007 were primarily due to restructuring charges and the write-down of the NATRECOR^® intangible asset. The increase in 2006 was 11.2% over the $13.1 billion in 2005. As a percent to sales, consolidated earnings before provision for taxes on income in 2007 was 21.7% versus 27.4% in 2006. The sections that follow highlight the significant components of the changes in consolidated earnings before provision for taxes on income.

Cost of Products Sold and Selling, Marketing and Administrative Expenses: Cost of products sold and selling, marketing and administrative expenses as a percent to sales were as follows:


% of Sales	2007			2006			2005

Cost of products sold		29.1	%		28.2			27.7
Percent point increase/(decrease) over the prior year		0.9			0.5			(0.8	)
Selling, marketing and administrative expenses		33.5			32.7			34.1
Percent point increase/(decrease) over the prior year		0.8			(1.4	)		(0.1	)

In 2007, there was an increase in the percent to sales of cost of products sold primarily due to the impact of newly acquired consumer brands. There was an increase in the percent to sales of selling, marketing and administrative expenses in 2007 primarily due to the impact of newly acquired consumer brands partially offset by cost containment efforts.

In 2006, there was an increase in the percent to sales of cost of products sold. This was due to unfavorable product mix and higher manufacturing costs in the Pharmaceutical and Consumer segments. There was a decrease in the percent to sales of selling, marketing and administrative expenses in 2006. This was a result of leveraging selling expenses and a reduction in advertising and promotional spending.

In 2005, there was a decrease in the percent to sales of cost of products sold. This was due to lower manufacturing costs primarily related to the CYPHER^® Sirolimus-eluting Coronary Stent, as well as ongoing cost containment activity across the organization, partially offset by the negative impact of pharmaceutical product mix. There was also a decrease in the percent to sales of selling, marketing and administrative expenses. This was due to cost containment initiatives in the Pharmaceutical segment partially offset by increases in investment spending in the Medical Devices and Diagnostics segment.

Research and Development: Research and development activities represent a significant part of the Company’s business. These expenditures relate to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of consumers and patients. Worldwide costs of research



40		JOHNSON & JOHNSON 2007 ANNUAL REPORT

activities, excluding in-process research and development charges, were as follows:


(Dollars in Millions)	2007			2006		2005

Research and development expense	$	7,680			7,125		6,462
Percent increase over the prior year		7.8	%		10.3		20.9
Percent of sales		12.6	%		13.4		12.8

Research and development expense as a percent of sales for the Pharmaceutical segment was 21.2% for 2007, 21.3% for 2006 and 20.2% for 2005. Research and development expense as a percent of sales for the Medical Devices and Diagnostics segment was 8.5% for 2007, 8.7% for 2006 and 8.2% for 2005. Research and development expense as a percent of sales for the Consumer segment was 3.9% for 2007, 4.0% for 2006 and 4.2% for 2005.

Research and development activities in the Pharmaceutical segment increased to $5.3 billion, or 6.1%, over 2006. The compound annual growth rate was approximately 13.8% for the five-year period since 2002.

The increased investment in research and development in all segments demonstrates the Company’s focus on knowledge-based products, and reflects a significant number of projects in late-stage development.

Restructuring: In 2007, the Company announced initiatives that are expected to generate pre-tax, annual cost savings of $1.3–$1.6 billion for 2008 in an effort to improve its overall cost structure. The Company recorded $745 million in related pre-tax charges. This action was taken to offset the anticipated negative impacts associated with generic competition in the Pharmaceutical segment and challenges in the drug-eluting stent market.

The Company’s Pharmaceuticals segment will reduce its cost base by consolidating certain operations, while continuing to invest in recently launched products and its late-stage pipeline of new products. The Cordis franchise is moving to a more integrated business model to address the market changes underway with drug-eluting stents and to better serve the broad spectrum of its patients’ cardiovascular needs, while reducing its cost base. This program will allow the Company to accelerate steps to standardize and streamline certain aspects of its enterprise-wide functions such as human resources, finance and information technology to support growth across the business, while also leveraging its scale more effectively in areas such as procurement to benefit its operating companies. See Note 22 for more details.

In-Process Research and Development: In 2007, the Company recorded a charge for in-process research and development (IPR&D) of $807 million before and after tax related to the acquisition of Conor Medsystems Inc. The IPR&D charge was included in the operating profit of the Medical Devices and Diagnostics segment.

In 2006, the Company recorded IPR&D charges of $559 million before tax related to the acquisitions of the Consumer Health-care business of Pfizer Inc., Vascular Control Systems, Inc., Ensure Medical, Inc., ColBar LifeScience Ltd., Hand Innovations LLC and Future Medical Systems S.A. The Consumer Healthcare business of Pfizer Inc. accounted for $320 million before tax of the IPR&D charges and was included in the operating profit of the Consumer segment. The IPR&D charges for all of the following acquisitions were included in the operating profit of the Medical Devices and Diagnostics segment. Vascular Control Systems, Inc., a privately held company focused on developing medical devices to treat fibroids and to control bleeding in obstetric and gynecologic applications, accounted for $87 million before tax of the IPR&D charges. Ensure Medical, Inc., a privately held company that develops devices for post-catheterization closure of the femoral artery, accounted for $66 million before tax of the IPR&D charges. ColBar LifeScience Ltd., a privately held company specializing in reconstructive medicine and tissue engineering, accounted for $49 million before tax of the IPR&D charges. Hand Innovations LLC, a privately held manufacturer of fracture fixation products for the upper extremities, accounted for $22 million before tax of the IPR&D charges. Future Medical Systems S.A., a privately held company that primarily develops, manufactures and markets arthroscopic fluid management systems, accounted for $15 million before tax of the IPR&D charges.

In 2005, the Company recorded IPR&D charges of $362 million before tax related to the acquisitions of TransForm Pharmaceuticals, Inc., Closure Medical Corporation, Peninsula Pharmaceuticals, Inc., and the international commercial rights to certain patents and know-how in the field of sedation and analgesia from Scott Lab, Inc. TransForm Pharmaceuticals, Inc., a company specializing in the discovery of superior formulations and novel crystalline forms of drug molecules, accounted for $50 million before tax of the IPR&D charges and was included in the operating profit of the Pharmaceutical segment. Closure Medical Corporation, a company with expertise and intellectual property in the biosurgicals market, accounted for $51 million before tax of the IPR&D charges and was included in the operating profit of the Medical Devices and Diagnostics segment. Peninsula Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections, accounted for $252 million before tax of the IPR&D charges and was included in the operating profit of the Pharmaceutical segment. The $9 million before tax IPR&D charge related to Scott Lab, Inc. referred to above was included in the operating profit of the Medical Devices and Diagnostics segment.

Other (Income) Expense, Net: Other (income) expense, net includes gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Development Corporation, gains and losses on the disposal of property, plant and equipment, currency gains and losses, minority interests, litigation settlements and liabilities and royalty income. The change in other (income) expense, net from 2007 to 2006 was an increase in expense of $1,205 million.

In 2007, other (income) expense, net included a charge of $678 million before tax related to the NATRECOR^® intangible asset write-down. A gain of $622 million associated with the Guidant acquisition agreement termination fee, less associated expenses, was included in 2006. In addition, 2006 also included expenses associated with the recording of additional product liability reserves and the integration costs associated with the acquisition of the Consumer Healthcare business of Pfizer Inc.

In 2005, other (income) expense, net included royalty income partially offset by several expense items, none of which were individually significant.



MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION		41

OPERATING PROFIT BY SEGMENT

Operating profits by segment of business were as follows:


						Percent of
						Segment Sales
(Dollars in Millions)	2007		2006			2007			2006

Consumer	$	2,277		1,374			15.7	%		14.1
Pharmaceutical		6,540		6,894			26.3			29.6
Med Devices and Diag		4,846		6,126			22.3			30.2

Total ⁽¹⁾		13,663		14,394			22.4			27.0
Less: Expenses/(Income) not allocated to segments ⁽²⁾		380		(193	)

Earnings before provision for taxes on income	$	13,283		14,587			21.7	%		27.4


⁽¹⁾		See Note 11 for more details.

⁽²⁾		Amounts not allocated to segments include interest (income)/expense, minority interest, and general corporate (income)/expense.

Consumer Segment: In 2007, Consumer segment operating profit increased 65.7% from 2006. As a percent to sales, 2007 operating profit increased to 15.7%. IPR&D expenses of $320 million as well as expenses associated with the Consumer Healthcare business of Pfizer Inc. integration were recorded during 2006. In 2006, Consumer segment operating profit decreased 13.7% and as a percent to sales declined to 14.1% over the prior year resulting from $320 million of IPR&D expenses as well as expenses associated with the Consumer Healthcare business of Pfizer Inc. integration recorded during 2006.

Pharmaceutical Segment: In 2007, Pharmaceutical segment operating profit decreased 5.1% from 2006. As a percent to sales, 2007 operating profit decreased to 26.3% resulting from $429 million of restructuring charges and $678 million for the NATRECOR^® intangible asset write-down in 2007. In 2006, Pharmaceutical segment operating profit increased 8.3% and as a percent to sales increased to 29.6% over the prior year. This increase was the result of $302 million of IPR&D recorded during 2005 partially offset by increases in research and development spending and lower gross margins in 2006.

Medical Devices and Diagnostics Segment: In 2007, the operating profit in the Medical Devices and Diagnostics segment decreased 20.9% from 2006. As a percent to sales, 2007, operating profit decreased to 22.3% resulting from $807 million of IPR&D expenses and $301 million of restructuring charges in 2007, while 2006 included the gain associated with the Guidant acquisition agreement termination fee, less associated expenses, of $622 million. In 2006, the Medical Devices and Diagnostics segment operating profit increased 16.9% and as a percent to sales increased 2.8% over the prior year. The primary driver of the improved operating profit was the Guidant acquisition agreement termination fee, less associated expenses, of $622 million recorded during 2006. This was partially offset by higher IPR&D charges of $239 million in 2006 versus $60 million in 2005. In addition, advertising and promotional expense leveraging were offset in part by increases in research and development spending.

Interest (Income) Expense: Interest income in 2007 decreased by $377 million due to a lower average cash balance. The decline in the average cash balance was due primarily to the acquisition of the Consumer Healthcare business of Pfizer Inc. on December 20, 2006. The cash balance, including marketable securities was $9.3 billion at the end of 2007, and averaged $6.6 billion as compared to the $15.7 billion average cash balance in 2006.

Interest expense in 2007 increased by $233 million due to a higher average debt balance. The net debt balance at the end of 2007 was $9.5 billion as compared to $6.6 billion at the end of 2006. The higher debt balance in 2007 was due to the debt associated with the acquisition of the Consumer Healthcare business of Pfizer Inc. and the Common Stock repurchase program in 2007.

Interest income in 2006 increased by $342 million due primarily to higher rates of interest, as well as a higher average cash balance, despite the $5.0 billion Common Stock repurchase program and an increase in acquisition activity as compared to prior year. The cash balance, including current marketable securities was $4.1 billion at the end of 2006 and averaged $15.7 billion, as compared to the $14.3 billion average cash balance in 2005.

Interest expense in 2006 increased slightly as compared to 2005 due to a higher average debt balance, from $2.6 billion in 2005 to $3.1 billion in 2006. This was partially offset by a decrease in interest rates.

Interest income in 2005 increased by $292 million due primarily to higher rates of interest, as well as a higher average cash balance. The cash balance, including current marketable securities, was $16.1 billion at the end of 2005 and averaged $14.3 billion, as compared to the $11.3 billion average cash balance in 2004.

Provision for Taxes on Income: The worldwide effective income tax rate was 20.4% in 2007, 24.2% in 2006 and 23.3% in 2005. The 2007 tax rate benefited from a one-time gain of $267 million related to an international business restructuring in certain countries, as well as increases in taxable income in lower tax jurisdictions relative to taxable income in higher tax jurisdictions and lower international tax rates in certain countries. The 2006 tax rate increased as compared to 2005 primarily due to a gain of $225 million recorded in 2005, which was partially offset by a benefit in 2006 related to the reversal of a tax allowance of $134 million associated with the international business. The 2005 effective tax rate benefited from the previously mentioned $225 million, due to the reversal of a tax liability previously recorded during the fiscal fourth quarter of 2004, related to a technical correction to the American Jobs Creation Act of 2004.

Liquidity and Capital Resources

CASH FLOWS

In 2007, cash flow from operations was $15.2 billion, an increase of $1.0 billion over 2006. The $1.0 billion increase in cash flow from operations is primarily attributable to non-cash expenses associated with the NATRECOR^® intangible asset write-down



42		JOHNSON & JOHNSON 2007 ANNUAL REPORT

and increased depreciation and amortization.

Net cash used by investing activities in 2007 was $6.1 billion versus $20.3 billion in 2006 which included the acquisition of the Consumer Healthcare business of Pfizer Inc. For a more detailed discussion on mergers and acquisitions, see Note 17. There was also a $1.6 billion net increase in purchases of investments, primarily marketable securities. Capital expenditures were $2.9 billion, $2.7 billion and $2.6 billion in 2007, 2006 and 2005, respectively.

Net cash used by financing activities decreased by $0.4 billion primarily due to a $1.1 billion decrease in the repurchase of Common Stock in 2007 and a $0.4 billion increase in proceeds from the exercise of stock options partially offset by $0.7 billion decrease in proceeds from short and long-term debt. There was also a $0.4 billion increase in dividends to shareholders in 2007.

Cash and current marketable securities were $9.3 billion at the end of 2007 as compared with $4.1 billion at the end of 2006, primarily due to cash flow from operations.

Cash generated from operations amounted to $14.2 billion in 2006, which was $2.4 billion more than the cash generated from operations in 2005 of $11.8 billion. The major factors contributing to the increase were a net income increase of $1.2 billion, net of the non-cash impact of IPR&D charges and a $2.7 billion increase in accounts payable and accrued liabilities. This was partially offset by a $0.9 billion increase in deferred taxes and a $0.8 billion increase in other current and non-current assets.

FINANCING AND MARKET RISK

The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency products costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S. Dollar from the December 30, 2007 market rates would increase the unrealized value of the Company’s forward contracts by $245 million. Conversely, a 10% depreciation of the U.S. Dollar from the December 30, 2007 market rates would decrease the unrealized value of the Company’s forward contracts by $299 million. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction and, therefore, would have no impact on future earnings and cash flows.

The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S. and foreign interest rates on the Company’s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company’s swap contracts by approximately $175 million. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction and therefore would have no impact on future cash flows.

The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an “A” (or equivalent) credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counter-party. Management believes the risk of loss is remote.

Total credit available to the Company approximates $8.0 billion, of which $6.4 billion expires September 25, 2008, and $1.6 billion expires September 27, 2012.

Total borrowings at the end of 2007 and 2006 were $9.5 billion and $6.6 billion, respectively. The increase in borrowings between 2006 and 2007 was a result of financing general corporate purposes and the Common Stock repurchase program in 2007. In 2007, net debt (cash and current marketable securities, net of debt) was $0.2 billion compared to net debt of $2.5 billion in 2006. Total debt represented 18.0% of total capital (shareholders’ equity and total debt) in 2007 and 14.4% of total capital in 2006. Shareholders’ equity per share at the end of 2007 was $15.25 compared with $13.59 at year-end 2006, an increase of 12.2%.

For the period ended December 30, 2007, there were no material cash commitments. Johnson & Johnson continues to be one of a few industrial companies with a Triple A credit rating. A summary of borrowings can be found in Note 6.



MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION		43

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The Company has contractual obligations, primarily lease, debt obligations and unfunded retirement plans, with no other significant obligations. To satisfy these obligations, the Company will use cash from operations. The following table summarizes the Company’s contractual obligations and their aggregate maturities as of December 30, 2007 (see Notes 4, 6 and 13 to the Audited Consolidated Financial Statements for further details):


					Unfunded
	Operating		Debt		Retirement
(Dollars in Millions)	Leases		Obligations⁽¹⁾		Plans		Total

2008	$	183		2,463		51		2,697
2009		151		247		55		453
2010		119		5		61		185
2011		94		23		64		181
2012		77		628		69		774
After 2012		113		6,171		416		6,700

Total	$	737		9,537		716		10,990


⁽¹⁾ Amounts do not include interest expense.

For tax matters, see Note 8.

SHARE REPURCHASE AND DIVIDENDS

On July 9, 2007, the Company announced that its Board of Directors approved a stock repurchase program, authorizing the Company to buy back up to $10.0 billion of the Company’s Common Stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes. The Company intends to fund the share repurchase program through a combination of available cash and debt. During 2007, the Company repurchased an aggregate of 55.8 million shares of Johnson & Johnson common stock under the current repurchase program at a cost of $3.6 billion. In addition the Company has an annual program to repurchase shares for use in employee stock and incentive plans.

The Company increased its dividend in 2007 for the 45th consecutive year. Cash dividends paid were $1.620 per share in 2007, compared with dividends of $1.455 per share in 2006 and $1.275 per share in 2005. The dividends were distributed as follows:


	2007		2006		2005

First quarter	$	0.375		0.330		0.285
Second quarter		0.415		0.375		0.330
Third quarter		0.415		0.375		0.330
Fourth quarter		0.415		0.375		0.330

Total	$	1.620		1.455		1.275

On January 2, 2008, the Board of Directors declared a regular cash dividend of $0.415 per share, payable on March 11, 2008, to shareholders of record as of February 26, 2008. The Company expects to continue the practice of paying regular cash dividends.

Other Information

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Management’s discussion and analysis of results of operations and financial condition are based on the Company’s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company’s operating results and financial condition. These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock options.

Revenue Recognition: The Company recognizes revenue from product sales when goods are shipped or delivered and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.

Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates, the largest being the Medicaid rebate provision, are estimated based on sales terms, historical experience, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third party sell-through and market research data, as well as internally generated information.

Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales.

Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are derived by estimating sales volumes for the incentive period and are recorded as products are sold. Promotional arrangements containing customer acceptance criteria are evaluated to determine the appropriate amounts to be deferred.

In addition, the Company enters into collaboration arrangements, which contain multiple revenue generating activities. The revenue for these arrangements is recognized as each activity is performed or delivered, based on the relative fair value. Upfront fees received as part of these arrangements, for which no further performance obligations exist, are recognized as revenue on the earlier of receipt of payment or collection is assured. If performance obligations exist, the Company will defer the upfront fees and recognize as earned over the obligation period.



44		JOHNSON & JOHNSON 2007 ANNUAL REPORT

Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a financial statement impact.

Below are tables which show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the years ended December 30, 2007 and December 31, 2006.

CONSUMER SEGMENT


	Balance at							Balance at
	Beginning				Payments/			End
(Dollars in Millions)	of Period		Accruals		Other			of Period

2007
Accrued rebates⁽¹⁾	$	164		492		(439	)		217
Accrued returns		92		257		(236	)		113
Accrued promotions		211		2,249		(2,163	)		297

Subtotal	$	467		2,998		(2,838	)		627

Reserve for doubtful accounts		42		17		12			71
Reserve for cash discounts		15		278		(270	)		23

Total	$	524		3,293		(3,096	)		721

2006
Accrued rebates⁽¹⁾	$	144		352		(332	)		164
Accrued returns		78		117		(103	)		92
Accrued promotions		172		1,555		(1,516	)		211

Subtotal	$	394		2,024		(1,951	)		467

Reserve for doubtful accounts		35		10		(3	)		42
Reserve for cash discounts		13		176		(174	)		15

Total	$	442		2,210		(2,128	)		524



⁽¹⁾		Includes reserve for customer rebates of $76 million at December 30, 2007 and $54 million at December 31, 2006, recorded as a contra asset.

PHARMACEUTICAL SEGMENT


	Balance at							Balance at
	Beginning				Payments/			End
(Dollars in Millions)	of Period		Accruals		Other			of Period

2007
Accrued rebates⁽¹⁾	$	1,233		3,175		(3,159	)		1,249
Accrued returns		324		36		(15	)		345
Accrued promotions		205		523		(465	)		263

Subtotal	$	1,762		3,734		(3,639	)		1,857

Reserve for doubtful accounts		30		—		(4	)		26
Reserve for cash discounts		29		531		(536	)		24

Total	$	1,821		4,265		(4,179	)		1,907

2006
Accrued rebates⁽¹⁾	$	1,119		2,857		(2,743	)		1,233
Accrued returns		287		67		(30	)		324
Accrued promotions		160		625		(580	)		205

Subtotal	$	1,566		3,549		(3,353	)		1,762

Reserve for doubtful accounts		36		—		(6	)		30
Reserve for cash discounts		29		503		(503	)		29

Total	$	1,631		4,052		(3,862	)		1,821



⁽¹⁾		Includes reserve for customer rebates of $321 million at December 30, 2007 and $227 million at December 31, 2006, recorded as a contra asset.

MEDICAL DEVICES AND DIAGNOSTICS SEGMENT


	Balance at							Balance at
	Beginning				Payments/			End
(Dollars in Millions)	of Period		Accruals		Other			of Period

2007
Accrued rebates⁽¹⁾	$	294		1,576		(1,534	)		336
Accrued returns		183		102		(95	)		190
Accrued promotions		41		136		(159	)		18

Subtotal	$	518		1,814		(1,788	)		544

Reserve for doubtful accounts		88		25		(17	)		96
Reserve for cash discounts		18		213		(207	)		24

Total	$	624		2,052		(2,012	)		664

2006
Accrued rebates⁽¹⁾	$	302		1,808		(1,816	)		294
Accrued returns		170		26		(13	)		183
Accrued promotions		56		104		(119	)		41

Subtotal	$	528		1,938		(1,948	)		518

Reserve for doubtful accounts		93		7		(12	)		88
Reserve for cash discounts		15		188		(185	)		18

Total	$	636		2,133		(2,145	)		624



⁽¹⁾		Includes reserve for customer rebates of $313 million at December 30, 2007 and $277 million at December 31, 2006, recorded as a contra asset.

The Company also earns service revenue for co-promotion of certain products. For all years presented, service revenues were less than 2% of total revenues and are included in sales to customers.

Income Taxes: Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on current tax regulations and rates. Changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. Management believes that changes in these estimates would not have a material effect on the Company’s results of operations, cash flows or financial position.

In 2007, the Company adopted FASB Interpretation 48 (FIN48), Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The interpretation also provides guidance on derecognition, classification and other matters. See Note 8 for further information regarding income taxes.

At December 30, 2007 and December 31, 2006, the cumulative amounts of undistributed international earnings were approximately $24.2 billion and $17.9 billion, respectively. The Company intends to continue to reinvest its undistributed international earnings to expand its international operations; therefore, no U.S. tax expense has been recorded to cover the undistributed portion not intended for repatriation.


MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION		45

Legal and Self Insurance Contingencies: The Company records accruals for various contingencies including legal proceedings and product liability cases as these arise in the normal course of business. The accruals are based on management’s judgment as to the probability of losses, opinions of legal counsel and, where applicable, actuarially determined estimates. Additionally, the Company records insurance receivable amounts from third-party insurers when recovery is probable. As appropriate, reserves against these receivables are recorded for estimated amounts that may not be collected from third-party insurers.

Long-Lived and Intangible Assets: The Company assesses changes in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company’s property, plant and equipment, goodwill and intangible assets. As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.

Employee Benefit Plans: The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, that cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, expected salary increases and health care cost trend rates. See Note 13 for further detail on these rates and the effect a rate change would have on the Company’s results of operations.

Stock Options: During the fiscal first quarter of 2006, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 123(R), Share Based Payment. The Company has applied the modified retrospective transition method to implement SFAS No. 123(R). Previously reported financial statements have been restated in accordance with the provisions of SFAS No. 123(R). See Note 10 for further information regarding stock options.

NEW ACCOUNTING PRONOUNCEMENTS

In June 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation 48 (FIN 48), Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The interpretation also provides guidance on derecognition, classification and other matters. FIN 48 is effective for the fiscal year 2007 and the Company adopted it in the first quarter of 2007.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. The statement is effective in the fiscal first quarter of 2008 except for non-financial assets and liabilities recognized or disclosed at fair value on a recurring basis, for which the effective date is fiscal years beginning after November 15, 2008. The Company believes that the adoption of SFAS No. 157 will not have a material effect on its results of operations, cash flows or financial position.

In February 2007, the FASB issued SFAS No. 159, Fair Value Option for Financial Assets and Financial Liabilities, which permits an entity to measure certain financial assets and financial liabilities at fair value. SFAS No. 159 is effective for fiscal year 2008 and the Company will adopt accordingly. The Company is assessing the impact of the adoption of SFAS No. 159 and currently does not believe that the adoption will have a material impact on its results of operations, cash flows or financial position.

In December 2007, FASB issued SFAS No. 141(R), Business Combinations, and No. 160, Noncontrolling Interests in Consolidated Financial Statements. These statements aim to improve, simplify, and converge internationally the accounting for business combinations and the reporting of noncontrolling interests in consolidated financial statements. These statements are effective for fiscal years beginning after December 15, 2008. SFAS No. 141(R) will have a significant impact on the manner in which the Company accounts for future acquisitions beginning in the fiscal year 2009. Significant changes include the capitalization of IPR&D, expensing of acquisition related restructuring actions and transaction related costs and the recognition of contingent purchase price consideration at fair value at the acquisition date. The Company believes that the adoption of SFAS No. 141(R) and SFAS No. 160 will not have a material effect on its results of operations, cash flows or financial position.

EITF Issue 07-1: Accounting for Collaborative Arrangements Related to the Development and Commercialization of Intellectual Property. This issue is effective for financial statements issued for fiscal years beginning after December 15, 2008. This issue addresses the income statement classification of payments made between parties in a collaborative arrangement. The adoption of EITF 07-1 is not expected to have a significant impact on the Company’s results of operations, cash flows or financial position.

EITF Issue 07-3: Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities. This issue is effective for financial statements issued for fiscal years beginning after December 15, 2007. This issue requires nonrefundable advance payments for research and development to be capitalized and recognized as an expense as related goods are delivered or services are performed. The adoption of EITF 07-3 is not expected to have a significant impact on the Company’s results of operations, cash flows or financial position.

ECONOMIC AND MARKET FACTORS

The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of health care. In response to these concerns, The Company has a long-standing policy of pricing products responsibly. For the period 1997-2007, in the United States, the weighted average compound annual growth rate of the Company’s net price increases for health care products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S. Consumer Price Index (CPI).

Inflation rates, even though moderate in many parts of the world during 2007, continue to have an effect on worldwide economies and, consequently, on the way companies operate. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases. The Company faces various worldwide health care changes that may result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement.


46		JOHNSON & JOHNSON 2007 ANNUAL REPORT

The Company also operates in an environment which has become increasingly hostile to intellectual property rights. Generic drug firms have filed ANDAs seeking to market generic forms of most of the Company’s key pharmaceutical products, prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in ANDA filings, the generic firms will then introduce generic versions of the product at issue, resulting in the potential for substantial market share and revenue losses for that product. For further information see the discussion on “Litigation Against Filers of Abbreviated New Drug Applications” in Note 18.

LEGAL PROCEEDINGS

The Company is involved in numerous product liability cases in the United States, many of which concern adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use which accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any liability results from such cases, it will be substantially covered by existing amounts accrued in the Company’s balance sheet under its self-insurance program and by third-party product liability insurance.

The Company is also involved in a number of patent, trademark and other lawsuits, as well as investigations, incidental to its business. The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities already accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company’s results of operations and cash flows for that period.

See Note 18 for further information regarding legal proceedings.

COMMON STOCK MARKET PRICES

The Company’s common stock is listed on the New York Stock Exchange under the symbol JNJ. The composite market price ranges for Johnson & Johnson common stock during 2007 and 2006 were:


	2007						2006
	High				Low		High			Low

First quarter	$	68.22				59.87		63.10			56.70
Second quarter		65.45				59.95		62.00			57.32
Third quarter		65.75				59.72		65.13			59.68
Fourth quarter		68.75				63.55		69.41			64.50
Year-end close			$	67.38					66.02

Cautionary Factors That May Affect Future Results

This Annual Report contains forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and anticipate results based on management’s plans that are subject to uncertainty. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things, discussions of future operations, financial performance, the Company’s strategy for growth, product development, regulatory approval, market position and expenditures.

Forward-looking statements are based on current expectations of future events. The Company cannot guarantee that any forward-looking statement will be accurate, although the Company believes that it has been reasonable in its expectations and assumptions. Investors should realize that if underlying assumptions prove inaccurate or that unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; U.S. and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; product efficacy or safety concerns resulting in product recalls or regulatory action.

The Company’s report on Form 10-K for the year ended December 30, 2007 includes, in Exhibit 99, a discussion of additional factors that could cause actual results to differ from expectations. The Company notes these factors as permitted by the Private Securities Litigation Reform Act of 1995.


MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION		47


Consolidated Balance Sheets		Johnson & Johnson and Subsidiaries


At December 30, 2007 and December 31, 2006 (Dollars in Millions Except Share and Per Share Data) (Note 1)	2007			2006

Assets
Current assets
Cash and cash equivalents (Notes 1 and 14)	$	7,770			4,083
Marketable securities (Notes 1 and 14)		1,545			1
Accounts receivable trade, less allowances for doubtful accounts $193 (2006,$160)		9,444			8,712
Inventories (Notes 1 and 2)		5,110			4,889
Deferred taxes on income (Note 8)		2,609			2,094
Prepaid expenses and other receivables		3,467			3,196

Total current assets		29,945			22,975


Marketable securities, non-current (Notes 1 and 14)		2			16
Property, plant and equipment, net (Notes 1 and 3)		14,185			13,044
Intangible assets, net (Notes 1 and 7)		14,640			15,348
Goodwill, net (Notes 1 and 7)		14,123			13,340
Deferred taxes on income (Note 8)		4,889			3,210
Other assets (Note 5)		3,170			2,623

Total assets	$	80,954			70,556


Liabilities and Shareholders’ Equity
Current liabilities
Loans and notes payable (Note 6)	$	2,463			4,579
Accounts payable		6,909			5,691
Accrued liabilities		6,412			4,587
Accrued rebates, returns and promotions		2,318			2,189
Accrued salaries, wages and commissions		1,512			1,391
Accrued taxes on income		223			724

Total current liabilities		19,837			19,161


Long-term debt (Note 6)		7,074			2,014
Deferred taxes on income (Note 8)		1,493			1,319
Employee related obligations (Notes 5 and 13)		5,402			5,584
Other liabilities		3,829			3,160

Total liabilities		37,635			31,238


Shareholders’ equity
Preferred stock —without par value (authorized and unissued 2,000,000 shares)		—			—
Common stock — par value $1.00 per share (Note 20) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)		3,120			3,120
Accumulated other comprehensive income (Note 12)		(693	)		(2,118	)
Retained earnings		55,280			49,290

		57,707			50,292
Less: common stock held in treasury, at cost (Note 20) (279,620,000 shares and 226,612,000 shares)		14,388			10,974

Total shareholders’ equity		43,319			39,318

Total liabilities and shareholders’ equity	$	80,954			70,556

See Notes to Consolidated Financial Statements


48		JOHNSON & JOHNSON 2007 ANNUAL REPORT


Consolidated Statements of Equity		Johnson & Johnson and Subsidiaries


										Note Receivable			Accumulated
										From Employee			Other					Treasury
				Comprehensive			Retained			Stock Ownership			Comprehensive			Common Stock		Stock
(Dollars in Millions) (Note 1)	Total			Income			Earnings			Plan (ESOP)			Income			Issued Amount		Amount

Balance, January 2, 2005	$	32,535						35,945			(11	)		(515	)		3,120		(6,004	)

Net earnings		10,060			10,060			10,060
Cash dividends paid		(3,793	)					(3,793	)
Employee stock compensation and stock option plans		1,485						27											1,458
Conversion of subordinated debentures		369						(132	)										501
Repurchase of common stock		(1,717	)					203											(1,920	)
Other comprehensive income, net of tax:
Currency translation adjustment		(415	)		(415	)								(415	)
Unrealized losses on securities		(16	)		(16	)								(16	)
Employee benefit plans		26			26									26
Gains on derivatives & hedges		165			165									165
Reclassification adjustment					(15	)

Total comprehensive income					9,805

Note receivable from ESOP		11									11

Balance, January 1, 2006	$	38,710						42,310			—			(755	)		3,120		(5,965	)

Net earnings		11,053			11,053			11,053
Cash dividends paid		(4,267	)					(4,267	)
Employee compensation and stock option plans		1,858						181											1,677
Conversion of subordinated debentures		26						(10	)										36
Repurchase of common stock		(6,722	)																(6,722	)
Other		23						23
Other comprehensive income, net of tax:
Currency translation adjustment		362			362									362
Unrealized losses on securities		(9	)		(9	)								(9	)
Employee benefit plans		(1,710	)		(34	)								(1,710	)
Losses on derivatives & hedges		(6	)		(6	)								(6	)
Reclassification adjustment					(9	)

Total comprehensive income					11,357

Balance, December 31, 2006	$	39,318						49,290			—			(2,118	)		3,120		(10,974	)

Net earnings		10,576			10,576			10,576
Cash dividends paid		(4,670	)					(4,670	)
Employee compensation and stock option plans		2,311						131											2,180
Conversion of subordinated debentures		9						(4	)										13
Repurchase of common stock		(5,607	)																(5,607	)
Adoption of FIN 48		(19	)					(19	)
Other		(24	)					(24	)
Other comprehensive income, net of tax:
Currency translation adjustment		786			786									786
Unrealized gains on securities		23			23									23
Employee benefit plans		670			670									670
Losses on derivatives & hedges		(54	)		(54	)								(54	)
Reclassification adjustment					(5	)

Total comprehensive income				11,996

Balance, December 30, 2007	$	43,319						55,280			—			(693	)		3,120		(14,388	)

See Notes to Consolidated Financial Statements



50		JOHNSON & JOHNSON 2007 ANNUAL REPORT


Consolidated Statements of Cash Flows		Johnson & Johnson and Subsidiaries


(Dollars in Millions) (Note 1)	2007			2006			2005

Cash flows from operating activities

Net earnings	$	10,576			11,053			10,060
Adjustments to reconcile net earnings to cash flows:
Depreciation and amortization of property and intangibles		2,777			2,177			2,093
Stock based compensation		698			659			540
Purchased in-process research and development		807			559			362
Intangible asset write-down (NATRECOR^®)		678			—			—
Deferred tax provision		(1,762	)		(1,168	)		(235	)
Accounts receivable allowances		22			(14	)		(31	)
Changes in assets and liabilities, net of effects from acquisitions:
Increase in accounts receivable		(416	)		(699	)		(568	)
Decrease/(increase) in inventories		14			(210	)		(396	)
Increase/(decrease) in accounts payable and accrued liabilities		2,642			1,750			(911	)
(Increase)/decrease in other current and non-current assets		(1,351	)		(269	)		542
Increase in other current and non-current liabilities		564			410			343


Net cash flows from operating activities		15,249			14,248			11,799


Cash flows from investing activities

Additions to property, plant and equipment		(2,942	)		(2,666	)		(2,632	)
Proceeds from the disposal of assets		230			511			154
Acquisitions, net of cash acquired (Note 17)		(1,388	)		(18,023	)		(987	)
Purchases of investments		(9,659	)		(467	)		(5,660	)
Sales of investments		7,988			426			9,187
Other (primarily intangibles)		(368	)		(72	)		(341	)


Net cash used by investing activities		(6,139	)		(20,291	)		(279	)


Cash flows from financing activities

Dividends to shareholders		(4,670	)		(4,267	)		(3,793	)
Repurchase of common stock		(5,607	)		(6,722	)		(1,717	)
Proceeds from short-term debt		19,626			6,385			1,215
Retirement of short-term debt		(21,691	)		(2,633	)		(732	)
Proceeds from long-term debt		5,100			6			6
Retirement of long-term debt		(18	)		(13	)		(196	)
Proceeds from the exercise of stock options/excess tax benefits		1,562			1,135			774


Net cash used by financing activities		(5,698	)		(6,109	)		(4,443	)


Effect of exchange rate changes on cash and cash equivalents		275			180			(225	)

(Decrease)/increase in cash and cash equivalents		3,687			(11,972	)		6,852
Cash and cash equivalents, beginning of year (Note 1)		4,083			16,055			9,203


Cash and cash equivalents, end of year (Note 1)	$	7,770			4,083			16,055


Supplemental cash flow data

Cash paid during the year for:
Interest	$	314			143			151
Income taxes		4,099			4,250			3,429
Supplemental schedule of noncash investing and financing activities

Treasury stock issued for employee compensation and stock option plans, net of cash proceeds	$	738			622			818
Conversion of debt		9			26			369

Acquisitions

Fair value of assets acquired	$	1,620			19,306			1,128
Fair value of liabilities assumed		(232	)		(1,283	)		(141	)


Net cash paid for acquisitions	$	1,388			18,023			987

See Notes to Consolidated Financial Statements



CONSOLIDATED FINANCIAL STATEMENTS		51

Notes to Consolidated Financial Statements

1. Summary of Significant Accounting Policies

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Johnson & Johnson and subsidiaries (the “Company”). Intercompany accounts and transactions are eliminated.

DESCRIPTION OF THE COMPANY AND BUSINESS SEGMENTS

The Company has approximately 119,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.

The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment manufactures and markets a broad range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. The Medical Devices and Diagnostics segment includes a broad range of products used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction and spinal care products; Ethicon’s wound care and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products and Vision Care’s disposable contact lenses.

NEW ACCOUNTING PRONOUNCEMENTS

In June 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation 48 (FIN 48), Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The interpretation also provides guidance on derecognition, classification and other matters. FIN 48 is effective for the fiscal year 2007 and the Company adopted it in the first quarter of 2007.

In September 2006, the FASB issued Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. The statement is effective in the fiscal first quarter of 2008 except for non-financial assets and liabilities recognized or disclosed at fair value on a recurring basis, for which the effective date is fiscal years beginning after November 15, 2008. The Company believes that the adoption of SFAS No. 157 will not have a material effect on its results of operations, cash flows or financial position.

In February 2007, the FASB issued SFAS No. 159, Fair Value Option for Financial Assets and Financial Liabilities, which permits an entity to measure certain financial assets and financial liabilities at fair value. SFAS No. 159 is effective for fiscal year 2008 and the Company will adopt accordingly. The Company is assessing the impact of the adoption of SFAS No.159 and currently does not believe that the adoption will have a material impact on its results of operations, cash flows or financial position.

In December 2007, FASB issued SFAS No. 141(R), Business Combinations, and No. 160, Noncontrolling Interests in Consolidated Financial Statements. These statements aim to improve, simplify, and converge internationally the accounting for business combinations and the reporting of noncontrolling interests in consolidated financial statements. These statements are effective for fiscal years beginning after December 15, 2008. SFAS No. 141(R) will have a significant impact on the manner in which the Company accounts for future acquisitions beginning in the fiscal year 2009. Significant changes include the capitalization of IPR&D, expensing of acquisition related restructuring actions and transaction related costs and the recognition of contingent purchase price consideration at fair value at the acquisition date. The Company believes that the adoption of SFAS No. 141(R) and SFAS No. 160 will not have a material effect on its results of operations, cash flows or financial position.

EITF Issue 07-1: Accounting for Collaborative Arrangements Related to the Development and Commercialization of Intellectual Property. This issue is effective for financial statements issued for fiscal years beginning after December 15, 2008. This issue addresses the income statement classification of payments made between parties in a collaborative arrangement. The adoption of EITF 07-1 is not expected to have a significant impact on the Company’s results of operations, cash flows or financial position.

CASH EQUIVALENTS

The Company considers securities with maturities of three months or less, when purchased, to be cash equivalents.

INVESTMENTS

Short-term marketable securities are carried at cost, which approximates fair value. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Long-term debt securities that the Company has the ability and intent to hold until maturity are carried at amortized cost, which also approximates fair value. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determi-



52		JOHNSON & JOHNSON 2007 ANNUAL REPORT

nation at each balance sheet date. The Company periodically reviews its investments in equity securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary.

PROPERTY, PLANT AND EQUIPMENT AND DEPRECIATION

Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:


Building and building equipment		20-40 years
Land and leasehold improvements		10-20 years
Machinery and equipment		2-13 years

The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 5 years.

The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the present value of future cash flows is less than the carrying value of these assets.

REVENUE RECOGNITION

The Company recognizes revenue from product sales when the goods are shipped or delivered and title and risk of loss pass to the customer. Provisions for certain rebates, sales incentives, trade promotions, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.

Sales returns are generally estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The returns reserve is based on historical return trends by product and by market as a percent to gross sales.

Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the year incurred. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. The Company also earns service revenue for co-promotion of certain products and includes it in sales to customers. Promotional arrangements containing customer acceptance criteria are evaluated to determine the appropriate amounts to be deferred.

SHIPPING AND HANDLING

Shipping and handling costs incurred were $934 million, $693 million and $736 million in 2007, 2006 and 2005, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.

INVENTORIES

Inventories are stated at the lower of cost or market determined by the first-in, first-out method.

INTANGIBLE ASSETS AND GOODWILL

SFAS No. 142 requires that goodwill and non-amortizable intangible assets be assessed annually for impairment. The Company completed the annual impairment test for 2007 in the fiscal fourth quarter and no impairment was determined. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if a triggering event occurs.

Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 7 for further details on Intangible Assets.

FINANCIAL INSTRUMENTS

The Company follows the provisions of SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, as amended. SFAS No. 133 requires that all derivative instruments be recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.

The Company uses forward exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third party purchases of raw materials denominated in foreign currency. The Company also uses currency swaps to manage currency risk primarily related to borrowings. Both of these types of derivatives are designated as cash flow hedges. Additionally, the Company uses forward exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.

The designation as a cash flow hedge is made at the entrance date into the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		53

income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. The fair value of a derivative instrument (i.e., forward foreign exchange contract, currency swap) is the aggregation, by currency, of all future cash flows discounted to its present value at prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate.

On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes in the cash flows of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings, and was insignificant in 2007, 2006 and 2005.

The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions.

PRODUCT LIABILITY

Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The accruals are adjusted periodically as additional information becomes available. As a result of cost and availability factors, effective November 1, 2005, the Company ceased purchasing third-party product liability insurance. Based on the availability of prior coverage, receivables for insurance recoveries related to product liability claims are recorded on an undiscounted basis, when it is probable that a recovery will be realized.

RESEARCH AND DEVELOPMENT

Research and development expenses are expensed as incurred. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.

ADVERTISING

Costs associated with advertising are expensed in the year incurred and are included in the selling, marketing and administrative expenses. Advertising expenses worldwide, which are comprised of television, radio, print media and Internet advertising, were $2.7 billion in 2007, $1.9 billion in 2006 and $2.1 billion in 2005.

INCOME TAXES

The Company intends to continue to reinvest its undistributed international earnings to expand its international operations; therefore, no U.S. tax expense has been recorded to cover the undistributed portion not intended for repatriation. At December 30, 2007 and December 31, 2006, the cumulative amount of undistributed international earnings were approximately $24.2 billion and $17.9 billion, respectively.

Deferred income taxes are recognized for tax consequences of temporary differences by applying enacted statutory tax rates, applicable to future years, to differences between the financial reporting and the tax basis of existing assets and liabilities.

NET EARNINGS PER SHARE

Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.

USE OF ESTIMATES

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. For instance, in determining annual pension and post-employment benefit costs, the Company estimates the rate of return on plan assets, and the cost of future health care benefits. Actual results may or may not differ from those estimates.

ANNUAL CLOSING DATE

The Company follows the concept of a fiscal year which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years, the fiscal year consists of 53 weeks.

2. Inventories

At the end of 2007 and 2006, inventories were comprised of:


(Dollars in Millions )	2007		2006

Raw materials and supplies	$	905		980
Goods in process		1,384		1,253
Finished goods		2,821		2,656

	$	5,110		4,889

3. Property, Plant and Equipment

At the end of 2007 and 2006, property, plant and equipment at cost and accumulated depreciation were:


(Dollars in Millions )	2007		2006

Land and land improvements	$	756		611
Buildings and building equipment		7,913		7,347
Machinery and equipment		14,554		13,108
Construction in progress		3,243		2,962

		26,466		24,028
Less accumulated depreciation		12,281		10,984

	$	14,185		13,044

The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in 2007, 2006 and 2005 was $130 million, $118 million and $111 million, respectively.

Depreciation expense, including the amortization of capitalized interest in 2007, 2006 and 2005 was $1.9 billion, $1.6 billion and $1.5 billion, respectively.

Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation


54		JOHNSON & JOHNSON 2007 ANNUAL REPORT

or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is recorded in earnings.

4. Rental Expense and Lease Commitments

Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases were approximately $302 million in 2007, $285 million in 2006 and $248 million in 2005.

The approximate minimum rental payments required under operating leases that have initial or remaining noncancelable lease terms in excess of one year at December 30, 2007 are:


(Dollars in Millions)										After
2008		2009		2010		2011		2012		2012		Total
$	183		151		119		94		77		113		737

Commitments under capital leases are not significant.

5. Employee Related Obligations

At the end of 2007 and 2006, employee related obligations were:


(Dollars in Millions)	2007		2006
Pension benefits	$	2,014		2,380
Postretirement benefits		2,134		2,009
Postemployment benefits		1,119		781
Deferred compensation		740		631

		6,007		5,801
Less current benefits payable		605		217

Employee related obligations	$	5,402		5,584

Prepaid employee related obligations of $481 million and $259 million for 2007 and 2006, respectively, are included in other assets on the consolidated balance sheet.

6. Borrowings

The components of long-term debt are as follows:


			Effective					Effective
(Dollars in Millions)	2007		Rate%			2006		Rate%
3% Zero Coupon Convertible Subordinated Debentures due 2020	$	178		3.00			182		3.00
4.95% Debentures due 2033		500		4.95			500		4.95
3.80% Debentures due 2013		500		3.82			500		3.82
6.95% Notes due 2029		294		7.14			293		7.14
6.73% Debentures due 2023		250		6.73			250		6.73
6.625% Notes due 2009		199		6.80			199		6.80
5.55% Debentures due 2017		1,000		5.55			—		—
5.95% Notes due 2037		995		5.99			—		—
5.50% Notes due 2024 (500 GBP1.9944)⁽²⁾		989		5.71			—		—
4.75% Notes due 2019 (1B Euro 1.4573)⁽²⁾		1,447		5.35			—		—
5.15% Debentures due 2012		599		5.18			—		—
Other (Includes Industrial Revenue Bonds)		132		—			99		—
		7,083		5.47	⁽¹⁾		2,023		5.23	⁽¹⁾
Less current portion		9		—			9		—

	$	7,074					2,014



(1)		Weighted average effective rate.

(2)		Translation rate at December 30, 2007.

The Company has access to substantial sources of funds at numerous banks worldwide. Total credit available to the Company approximates $8.0 billion of which $6.4 billion expire September 25, 2008, and $1.6 billion expire September 27, 2012. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or London Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under the agreements are not material.

The Company filed a shelf registration with the Securities and Exchange Commission that became effective November 13, 2006 and which enables the Company to issue up to $10 billion in debt securities and warrants to purchase debt securities. The Company issued bonds in August 2007 for a total of $2.6 billion and in November 2007 for a total of $2.4 billion for general corporate purposes and the Common Stock repurchase program in 2007. At December 30, 2007 the Company had $5.0 billion remaining on the shelf registration.

On July 28, 2000, ALZA Corporation, a subsidiary of the Company completed a private offering of the 3% Zero Coupon Convertible Subordinated Debentures, which were issued at a price of $551.26 per $1,000 principal amount at maturity. At December 30, 2007 the outstanding 3% Debentures had a total principal amount at maturity of $258.8 million with a yield to maturity of 3% per annum, computed on a semiannual bond equivalent basis. There are no periodic interest payments. Under the terms of the 3% debentures, holders are entitled to convert their debentures into approximately 15.0 million shares of Johnson & Johnson common stock at a price of $40.102 per share. Approximately 11.4 million shares have been issued as of December 30, 2007, due to voluntary conversions by note holders. At the option of the holder, the 3% Debentures may be repurchased by the Company on July 28, 2008 or 2013, at a purchase price equal to the issue price plus accreted original issue discount to such purchase date. The Company, at its option, may elect to deliver either Johnson & Johnson common stock or cash, or a combination of stock and cash, in the event of repurchase of the 3% Debentures. The Company, at its option, may also redeem any or all of the 3% Debentures after July 28, 2003 at the issue price plus accreted original issue discount. At December 30, 2007 and December 31, 2006, the fair value based on quoted market value of the 3% Debentures was $240.0 million and $250.7 million, respectively.

Short-term borrowings and the current portion of long-term debt amounted to approximately $2.5 billion at the end of 2007, of which $2.0 billion was raised under the Commercial Paper Program. The remainder represents principally local borrowing by international subsidiaries.

Aggregate maturities of long-term obligations commencing in 2007 are:


(Dollars in Millions)										After
2008		2009		2010		2011		2012		2012
$	9		247		5		23		628		6,171

CERTAIN BUSINESS RELATIONSHIPS

A member of the Company’s Board of Directors is the former Chief Executive Officer of a major bank. This bank has provided services to the Company, for which the payments made were not significant for either the Company or the bank in 2007, 2006 or 2005. The Company plans to engage the bank to provide


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		55

services, including investment banking services, to the Company in 2008. The Company does not anticipate payments for these services to be significant to either the bank or the Company in 2008.

7. Intangible Assets and Goodwill

At the end of 2007 and 2006, the gross and net amounts of intangible assets and goodwill were:


(Dollars in Millions)	2007		2006
Trademarks (non-amortizable) — gross	$	6,457		6,609
Less accumulated amortization		144		134

Trademarks (non-amortizable) — net	$	6,313		6,475

Patents and trademarks — gross	$	4,597		5,282
Less accumulated amortization		1,615		1,695

Patents and trademarks — net	$	2,982		3,587

Other intangibles — gross	$	7,399		6,923
Less accumulated amortization		2,054		1,637

Other intangibles — net	$	5,345		5,286

Subtotal intangible assets — gross	$	18,453		18,814
Less accumulated amortization		3,813		3,466

Subtotal intangible assets — net	$	14,640		15,348

Goodwill — gross	$	14,866		14,075
Less accumulated amortization		743		735

Goodwill — net	$	14,123		13,340

Total intangible assets and goodwill — gross	$	33,319		32,889
Less accumulated amortization		4,556		4,201

Total intangible assets and goodwill — net	$	28,763		28,688

Goodwill as of December 30, 2007 and December 31, 2006, as allocated by segment of business is as follows:


					Med Dev
(Dollars in Millions)	Consumer		Pharm		and Diag		Total
Goodwill at January 1, 2006	$	1,090		874		4,026		5,990

Acquisitions		6,720		—		533		7,253
Translation/other		56		28		13		97

Goodwill at December 31, 2006	$	7,866		902		4,572		13,340

Acquisitions		3		—		449		452
Translation/other		256		62		13		331

Goodwill at December 30, 2007	$	8,125		964		5,034		14,123

The weighted average amortization periods for patents and trademarks and other intangible assets are 16 years and 28 years, respectively. The amortization expense of amortizable intangible assets for the fiscal years ended December 30, 2007, December 31, 2006 and January 1, 2006 was $844 million, $594 million and $521 million before tax, respectively. Certain patents and intangible assets were written down to fair value during fiscal years 2007, 2006 and 2005, with the resulting charge included in amortization expense. The reduction in total patent and trademarks compared to 2006 is primarily due to a write-down of $678 million before tax, related to the NATRECOR^® intangible asset. The remaining unamortized intangible value associated with NATRECOR^® was $200 million at the end of 2007. This charge results from revised estimates of future cash flows from this product due primarily to a recent decline in NATRECOR^® sales trends. NATRECOR^® will continue to be marketed by Scios Inc., a subsidiary of the Company.

The estimated amortization expense for the five succeeding years approximates $753 million before tax, per year. Substantially all of the amortization expense is included in cost of products sold.

8. Income Taxes

The provision for taxes on income consists of:


(Dollars in Millions )	2007			2006			2005
Currently payable:
U.S. taxes	$	2,990			3,625			2,181
International taxes		1,479			1,077			1,110

		4,469			4,702			3,291

Deferred:
U.S. taxes		(722	)		(726	)		77
International taxes		(1,040	)		(442	)		(312	)

		(1,762	)		(1,168	)		(235	)

	$	2,707			3,534			3,056

A comparison of income tax expense at the U.S. statutory rate of 35% in 2007, 2006 and 2005, to the Company’s effective tax rate is as follows:


(Dollars in Millions )	2007			2006			2005
U.S.	$	5,237			8,110			6,949
International		8,046			6,477			6,167

Earnings before taxes on income:	$	13,283			14,587			13,116

Tax rates:
U.S. statutory rate		35.0	%		35.0			35.0
Puerto Rico and Ireland operations		(8.8	)		(7.5	)		(7.3	)
Research and orphan drug tax credits		(0.8	)		(0.7	)		(0.7	)
U.S. state and local		2.1			1.6			1.1
International subsidiaries excluding Ireland		(7.3	)		(3.5	)		(2.7	)
Technical Corrections Act impact on 2004 tax liability		—			—			(1.7	)
U.S. manufacturing deduction		(0.3	)		(0.2	)		(0.2	)
In process research and development (IPR&D )		2.1			0.6			0.9
U.S. Tax international income		(1.9	)		(0.7	)		(0.7	)
All other		0.3			(0.4	)		(0.4	)

Effective tax rate		20.4	%		24.2			23.3

The Company has subsidiaries manufacturing in Ireland under an incentive tax rate. In addition, the Company has subsidiaries operating in Puerto Rico under various tax incentive grants. Also, the U.S. possessions tax credit, which expired in 2006, applies to certain operations in Puerto Rico. The decrease in the 2007 tax rate was mainly attributed to increases in taxable income in lower tax jurisdictions relative to taxable income in higher jurisdictions and lower international tax rates in certain countries. The international tax rate also benefited from a business restructuring of certain international subsidiaries, resulting in a one-time benefit of $267 million, which reduced the effective tax rate by 2%.


56		JOHNSON & JOHNSON 2007 ANNUAL REPORT

The increase in the 2006 tax rate was mainly due to the reversal of a tax liability of $225 million reported in the 2005 tax provision which resulted from a technical correction to the American Jobs Creation Act of 2004. This was partially offset by a benefit reported in 2006 for the reversal of tax allowances of $134 million associated with the international business.

Temporary differences and carry forwards for 2007 and 2006 are as follows:


	2007					2006
	Deferred Tax					Deferred Tax
(Dollars in Millions)	Asset		Liability			Asset		Liability
Employee related obligations	$	1,727					1,691
Stock based compensation		1,173					1,006
Depreciation				(463	)				(450	)
Non-deductible intangibles				(1,554	)				(2,263	)
International R&D capitalized for tax		1,773					1,483
Reserves & liabilities		1,155					845
Income reported for tax purposes		487					373
Miscellaneous international		1,011		(127	)		663		(298	)
Capitalized intangibles		89					126
Miscellaneous U.S.		708					747

Total deferred income taxes	$	8,123		(2,144	)		6,934		(3,011	)

The difference between the net deferred tax on income per the balance sheet and the net deferred tax above is included in taxes on income on the balance sheet.

The Company adopted FIN No. 48, Accounting for Uncertainty in Income Taxes effective January 1, 2007 which resulted in the recognition of an additional $19 million of previously unrecognized tax benefits, with the corresponding adjustment to retained earnings. The Company had $1.3 billion of gross unrecognized tax benefits, $1.1 billion net unrecognized tax benefits, as of January 1, 2007 including the previous adjustment mentioned above. The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. During the year ended December 30, 2007 the Company recognized $42 million of interest income and $58 million of interest expense, with an after-tax impact of $10 million. The total amount of accrued interest was $187 million and $171 million in 2007 and 2006, respectively.

The following table summarizes the activity related to unrecognized tax benefits:


(Dollars in Millions)	Total
Balance as of January 1, 2007	$	1,262
Increases related to current year tax positions		487
Increases related to prior period tax positions		77
Decreases related to prior period tax positions		(117	)
Settlements		(14	)
Lapse of statute of limitations		(42	)

Balance as of December 30, 2007	$	1,653

Included in the unrecognized tax benefits of approximately $1.7 billion at December 30, 2007, are $1.4 billion of potential tax benefits that, if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. The U.S. Internal Revenue Service (IRS) has completed the audit for tax years through 1999; however, the years 1996 though 1999 remain open while a limited number of issues are being considered at the IRS appeals level, which the Company expects to be resolved within the next twelve months. In other major jurisdictions where the Company conducts business, the years remain open generally back to the year 2001 with some jurisdictions remaining open as far back as 1995. The Company does not expect that the total amount of unrecognized tax benefits will significantly change over the next twelve months. The Company does not expect a significant payment within the next twelve months, and is not able to provide a reasonably reliable estimate of the timing of any future tax payments, relating to uncertain tax positions.

9. International Currency Translation

For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency.

In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. This equity account includes the results of translating all balance sheet assets and liabilities at current exchange rates, except for those located in highly inflationary economies. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.

An analysis of the changes during 2007, 2006 and 2005 for foreign currency translation adjustments is included in Note 12.

Net currency transaction and translation gains and losses included in other (income) expense were losses of $23 million, $18 million and $32 million in 2007, 2006 and 2005, respectively.

10. Common Stock, Stock Option Plans and Stock Compensation Agreements

STOCK OPTIONS

At December 30, 2007, the Company had 15 stock-based compensation plans. The shares outstanding are for contracts under the Company’s 1995 and 2000 Stock Option Plans, the 2005 Long-Term Incentive Plan, the 2000 Stock Compensation Plan, the 1997 Non-Employee Director’s Plan and the Centocor, Innovasive Devices, ALZA, Inverness, and Scios Stock Option Plans. During 2007, no options or restricted shares were granted under any of these plans except under the 2005 Long-Term Incentive Plan.

The compensation cost recorded under SFAS No. 123(R) that has been charged against income for these plans was $698 million for 2007, $659 million for 2006 and $540 million for 2005. The total income tax benefit recognized in the income statement for share-based compensation costs was $238 million for 2007, $228 million for 2006 and $189 million for 2005. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.

Stock options expire 10 years from the date of grant and vest over service periods that range from six months to five


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		57

years. All options are granted at the average of the high and low prices of the Company’s common stock on the New York Stock Exchange on the date of grant. Under the 2005 Long-Term Incentive Plan, the Company may issue up to 260 million shares of Common Stock. Shares available for future grants under the 2005 Long-Term Incentive Plan were 194.5 million at the end of 2007.

The Company settles employee stock option exercises with treasury shares. Treasury shares are replenished throughout the year for the number of shares used to settle employee stock option exercises.

The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Starting in 2006, expected volatility represents a blended rate of 4-year daily historical average volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. Prior to 2006, expected volatility was based on 5-year weekly historical volatility rate. Historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant.

The average fair value of options granted was $11.67, $12.22 and $15.48 in 2007, 2006 and 2005, respectively. The fair value was estimated based on the weighted average assumptions of:


	2007			2006			2005

Risk-free rate		4.78	%		4.60	%		3.72	%
Expected volatility		14.7	%		19.6	%		25.0	%
Expected life	6.0 yrs			6.0 yrs			5.0 yrs
Dividend yield		2.50	%		2.50	%		1.93	%

A summary of option activity under the Plan as of December 30, 2007, December 31, 2006 and January 1, 2006 and changes during the years ending on those dates is presented below:


						Aggregate
				Weighted		Intrinsic
	Outstanding			Average		Value
(Shares in Thousands)	Shares			Exercise Price		(Dollars in Millions)

Shares at January 2, 2005		229,004		$	48.62	$	3,390

Options granted		47,556			66.16
Options exercised		(21,733	)		34.19
Options canceled/forfeited		(6,285	)		55.84

Shares at January 1, 2006		248,542			53.05	$	2,031

Options granted		28,962			58.38
Options exercised		(26,152	)		42.80
Options canceled/forfeited		(8,425	)		59.33

Shares at December 31, 2006		242,927			54.57	$	2,788

Options granted		26,789			65.61
Options exercised		(33,224	)		45.92
Options canceled/forfeited		(7,863	)		63.00

Shares at December 30, 2007		228,629		$	56.83	$	2,411

The total intrinsic value of options exercised was $625.4 million, $541.5 million and $664.0 million in 2007, 2006 and 2005, respectively. The total unrecognized compensation cost was $651.9 million as of December 30, 2007, $648.8 million as of December 31, 2006 and $659.6 million as of January 1, 2006.

The weighted average period for this cost to be recognized was 1.01 years for 2007, 0.99 years for 2006 and 1.15 years for 2005.

The following table summarizes stock options outstanding and exercisable at December 30, 2007:


(Shares in Thousands)	Outstanding						Exercisable
					Average				Average
Exercise			Average		Exercise				Exercise
Price Range	Options		Life⁽¹⁾		Price		Options		Price

$ 3.62-$29.44		744		2.2	$	20.57		744	$	20.57
$30.55-$40.16		8,304		1.0		39.67		8,304		39.67
$40.98-$50.08		14,491		2.0		49.48		14,491		49.48
$50.39-$52.11		22,892		2.8		50.70		22,892		50.70
$52.20-$53.77		27,615		5.0		52.22		27,615		52.22
$53.93-$54.89		33,094		6.0		53.93		31,434		53.93
$55.01-$58.25		31,447		4.1		57.30		31,414		57.30
$58.34-$66.08		51,273		8.5		61.96		416		61.18
$66.18-$68.26		38,769		7.1		66.19		—		—

		228,629		5.6	$	56.83		137,310	$	52.33


⁽¹⁾		Average contractual life remaining in years.

Stock options exercisable at December 31, 2006 and January 1, 2006 were 131,077 at an average price of $50.23 and an average life of 5.9 years, and 119,390 options at an average price of $47.90 and an average life of 6.4 years, respectively.

RESTRICTED SHARE UNITS

The Company grants restricted share units with a vesting period of three years. The Company settles employee stock issuance with treasury shares. Treasury shares are replenished throughout the year for the number of shares used for employee stock issuances.

A summary of share activity under the Plan as of December 30, 2007:


	Outstanding
(Shares in Thousands)	Shares

Shares at January 1, 2006		111
Shares granted		7,320
Shares issued		(33	)
Shares canceled/forfeited		(513	)

Shares at December 31, 2006		6,885
Shares granted		8,029
Shares issued		(33	)
Shares canceled/forfeited		(1,220	)

Shares at December 30, 2007		13,661

The average fair value of the restricted share units granted was $60.86 and $54.17 in 2007 and 2006, respectively using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units settled was $1.8 million and $1.7 million in 2007 and 2006, respectively.



58		JOHNSON & JOHNSON 2007 ANNUAL REPORT

11. Segments of Business⁽¹⁾and Geographic Areas


	Sales to Customers⁽²⁾
(Dollars in Millions)	2007		2006		2005

Consumer — United States	$	6,408		4,573		4,405
International		8,085		5,201		4,691

Total		14,493		9,774		9,096

Pharmaceutical — United States		15,603		15,092		14,478
International		9,263		8,175		7,844

Total		24,866		23,267		22,322

Medical Devices and Diagnostics — United States		10,433		10,110		9,494
International		11,303		10,173		9,602

Total		21,736		20,283		19,096

Worldwide total	$	61,095		53,324		50,514


	Operating Profit							Identifiable Assets
(Dollars in Millions)	2007⁽⁵⁾		2006⁽⁶⁾			2005⁽⁷⁾		2007		2006		2005

Consumer	$	2,277		1,374			1,592	$	26,550		25,380		6,275
Pharmaceutical		6,540		6,894			6,365		19,780		18,799		16,091
Medical Devices and Diagnostics		4,846		6,126			5,240		19,978		18,601		16,540

Total		13,663		14,394			13,197		66,308		62,780		38,906
Less: (Income)/Expenses not allocated to segments⁽³⁾		380		(193	)		81
General corporate⁽⁴⁾									14,646		7,776		19,958

Worldwide total	$	13,283		14,587			13,116	$	80,954		70,556		58,864


	Additions to Property,						Depreciation and
	Plant & Equipment						Amortization
(Dollars in Millions)	2007		2006		2005		2007		2006		2005

Consumer	$	504		344		321	$	472		255		232
Pharmaceutical		1,137		1,246		1,388		1,033		929		918
Medical Devices and Diagnostics		919		823		785		1,080		861		821

Segments total		2,560		2,413		2,494		2,585		2,045		1,971
General corporate		382		253		138		192		132		122

Worldwide total	$	2,942		2,666		2,632	$	2,777		2,177		2,093


	Sales to Customers⁽²⁾						Long-Lived Assets⁽⁸⁾
(Dollars in Millions)	2007		2006		2005		2007		2006		2005

United States	$	32,444		29,775		28,377	$	21,685		22,432		15,355
Europe		15,644		12,786		12,187		15,578		14,443		5,646
Western Hemisphere excluding U.S.		4,681		3,542		3,087		3,722		3,108		957
Asia-Pacific, Africa		8,326		7,221		6,863		1,261		1,206		596

Segments total		61,095		53,324		50,514		42,246		41,189		22,554
General corporate								702		543		451
Other non long-lived assets								38,006		28,824		35,859

Worldwide total	$	61,095		53,324		50,514	$	80,954		70,556		58,864


⁽¹⁾		See Note 1 for a description of the segments in which the Company operates.

⁽²⁾ ⁽³⁾		Export sales and intersegment sales are not significant. In 2007, 2006 and 2005, the Company did not have a customer that represented 10% of total revenues. Amounts not allocated to segments include interest (income)/expense, minority interest and general corporate (income)/expense.

⁽⁴⁾		General corporate includes cash and marketable securities.

⁽⁵⁾		Includes $745 million of restructuring expense, comprised of $15 million, $429 million, and $301 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment Includes $807 million of In-Process Research and Development (IPR&D). The Pharmaceutical segment also includes $678 million for the write-down of the NATRECOR^® intangible asset.

⁽⁶⁾		Includes $320 million and $239 million of IPR&D for the Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes the Guidant acquisition agreement termination fee, less associated expenses, of $622 million.

⁽⁷⁾		Includes $302 million and $60 million of IPR&D for the Pharmaceutical and Medical Devices and Diagnostics segments, respectively.

⁽⁸⁾		Long-lived assets include property, plant and equipment, net for 2007, 2006 and 2005 of $14,185, $13,044 and $10,830, respectively, and intangible assets, net for 2007, 2006 and 2005 of $28,763, $28,688 and $12,175, respectively.



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		59

12. Accumulated Other Comprehensive Income

Components of other comprehensive income/(loss) consist of the following:


													Total
				Unrealized						Gains/			Accumulated
	Foreign			Gains/						(Losses) on			Other
	Currency			(Losses) on			Employee			Derivatives			Comprehensive
(Dollars in Millions)	Translation			Securities			Benefit Plans			& Hedges			Income/(Loss)

Jan. 2, 2005	$	(105	)		86			(346	)		(150	)		(515	)
2005 changes
Net change due to hedging transactions		—			—			—			112
Net amount reclassed to net earnings		—			—			—			53

Net 2005 changes		(415	)		(16	)		26			165			(240	)

Jan. 1, 2006	$	(520	)		70			(320	)		15			(755	)
2006 changes
Net change due to hedging transactions		—			—			—			17
Net amount reclassed to net earnings		—			—			—			(23	)

Net 2006 changes		362			(9	)		(1,710	)		(6	)		(1,363	)

Dec. 31, 2006	$	(158	)		61			(2,030	)		9			(2,118	)
2007 changes
Net change due to hedging transactions		—			—			—			(78	)
Net amount reclassed to net earnings		—			—			—			24

Net 2007 changes		786			23			670			(54	)		1,425

Dec. 30, 2007	$	628			84			(1,360	)		(45	)		(693	)

Total comprehensive income for 2007 includes reclassification adjustment gains of $7 million realized from the sale of equity securities and the associated tax expense of $2 million.

Total other comprehensive income for 2006 includes reclassification adjustment gains of $13 million realized from the sale of equity securities and the associated tax expense of $4 million.

Total other comprehensive income for 2005 includes reclassification adjustment gains of $23 million realized from the sale of equity securities and the associated tax expense of $8 million.

The tax effect on the unrealized gains/(losses) on the equity securities balance is an expense of $46 million, $33 million and $38 million in 2007, 2006 and 2005, respectively. The tax effect related to employee benefit plans was $349 million, $891 million and $160 million in 2007, 2006 and 2005, respectively. The tax effect on the gains/(losses) on derivatives and hedges are gains of $24 million in 2007, and losses of $4 million and $11 million in 2006 and 2005, respectively. See Note 15 for additional information relating to derivatives and hedging.

The currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in international subsidiaries.

13. Pensions and Other Benefit Plans

The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides postretirement benefits, primarily health care, to all U.S. retired employees and their dependents.

Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.

Retirement plan benefits are primarily based on the employee’s compensation during the last three to five years before retirement and the number of years of service. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.

The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future.

The Company uses the date of its consolidated financial statements (December 30, 2007 and December 31, 2006, respectively) as the measurement date for all U.S. and international retirement and other benefit plans.

In September 2006, Statement of Financial Accounting Standards (SFAS) No. 158, Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans was issued and amends further the disclosure requirements for pensions and other postretirement benefits. This Statement was an amendment of FASB Statements No. 87, 88, 106 and 132(R). The incremental effect of applying FASB No. 158 was a $1.7 billion reduction in Shareholder’s Equity, net of deferred taxes.



60		JOHNSON & JOHNSON 2007 ANNUAL REPORT

Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2007, 2006 and 2005 include the following components:


	Retirement Plans									Other Benefit Plans
(Dollars in Millions)	2007			2006			2005			2007			2006			2005

Service cost	$	597			552			462		$	140			122			56
Interest cost		656			570			488			149			136			87
Expected return on plan assets		(809	)		(701	)		(579	)		(2	)		(3	)		(3	)
Amortization of prior service cost		10			10			12			(7	)		(7	)		(7	)
Amortization of net transition asset		1			(1	)		(2	)		—			—			—
Recognized actuarial losses		186			251			219			66			74			25
Curtailments and settlements		5			4			2			—			—			—
Net periodic benefit cost	$	646			685			602		$	346			322			158

The net periodic benefit cost attributable to U.S. retirement plans was $379 million in 2007, $423 million in 2006 and $370 million in 2005.

Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other postretirement plans:


(Dollars in Millions)

Amortization of net transition obligation	$	2
Amortization of net actuarial losses		132
Amortization of prior service cost		5

The weighted-average assumptions in the following table represent the rates used to develop the actuarial present value of projected benefit obligation for the year listed and also the net periodic benefit cost for the following year.


	Retirement Plans							Other Benefit Plans
(Dollars in Millions)	2007			2006		2005		2007			2006		2005

U.S. Benefit Plans

Discount rate		6.50	%		6.00		5.75		6.50	%		6.00		5.75
Expected long-term rate of return on plan assets		9.00			9.00		9.00		9.00			9.00		9.00
Rate of increase in compensation levels		4.50			4.50		4.50		4.50			4.50		4.50
International Benefit Plans

Discount rate		5.50	%		5.00		4.75		6.50	%		6.00		5.00
Expected long-term rate of return on plan assets		8.25			8.00		8.25		—			—		—
Rate of increase in compensation levels		4.00			3.75		3.75		4.50			4.50		4.25

The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities.

The expected long-term rate of return on plan assets assumption is determined using a building block approach, considering historical averages and real returns of each asset class. In certain countries, where historical returns are not meaningful, consideration is given to local market expectations of long-term returns.

The following table displays the assumed health care cost trend rates, for all individuals:


Health Care Plans	2007			2006

Health care cost trend rate assumed for next year		9.00	%		9.00
Rate to which the cost trend rate is assumed to decline (ultimate trend)		5.00	%		4.50
Year the rate reaches the ultimate trend rate		2014			2012

A one-percentage-point change in assumed health care cost trend rates would have the following effect:


	One-Percentage-		One-Percentage-
(Dollars in Millions)	Point Increase		Point Decrease

Health Care Plans

Total interest and service cost	$	35	$	(27	)
Postretirement benefit obligation		320		(259	)



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		61

The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2007 and 2006 for the Company’s defined benefit retirement plans and other postretirement plans:


	Retirement Plans						Other Benefit Plans
(Dollars in Millions)	2007			2006			2007			2006
Change in Benefit Obligation

Projected benefit obligation — beginning of year	$	11,660			10,171		$	2,668			2,325
Service cost		597			552			140			122
Interest cost		656			570			149			136
Plan participant contributions		62			47			—			—
Amendments		14			7			—			—
Actuarial (gains) losses		(876	)		(99	)		(1	)		130
Divestitures & acquisitions		79			443			8			101
Curtailments & settlements		(46	)		(7	)		—			—
Benefits paid from plan		(481	)		(402	)		(255	)		(147	)
Effect of exchange rates		337			378			12			1

Projected benefit obligation — end of year	$	12,002			11,660		$	2,721			2,668

Change in Plan Assets

Plan assets at fair value — beginning of year	$	9,538			8,108			30			34
Actual return on plan assets		743			966			4			2
Company contributions		317			259			250			141
Plan participant contributions		62			47			—			—
Settlements		(38	)		(7	)		—			—
Divestitures & acquisitions		55			300			—			—
Benefits paid from plan assets		(481	)		(402	)		(255	)		(147	)
Effect of exchange rates		273			267			—			—

Plan assets at fair value — end of year	$	10,469			9,538		$	29			30

Funded status at — end of year	$	(1,533	)		(2,122	)	$	(2,692	)		(2,638	)

Amounts Recognized in the Company’s Balance Sheet consist of the following:

Non-current assets	$	481			259			—			—
Current liabilities		(43	)		(26	)		(262	)		(81	)
Non-current liabilities		(1,971	)		(2,355	)		(2,430	)		(2,557	)

Total recognized in the consolidated balance sheet — end of year	$	(1,533	)		(2,122	)	$	(2,692	)		(2,638	)


Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:

Net actuarial loss (gain)	$	1,027			1,996		$	1,013			1,046
Prior service cost (credit)		51			44			(36	)		(42	)
Unrecognized net transition asset		7			7			—			—
Total before tax effects	$	1,085			2,047		$	977			1,004


Accumulated Benefit Obligations — end of year	$	10,282			9,804


Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income

Net periodic benefit cost	$	646					$	346

Net actuarial loss (gain)		(555	)					11
Amortization of net actuarial loss		(435	)					(13	)
Prior service cost		(9	)					(34	)
Amortization of prior service cost		14						6
Effect of exchange rates		23						3

Total recognized in other comprehensive income, before tax	$	(962	)				$	(27	)

Total recognized in net periodic benefit cost and other comprehensive income	$	(316	)				$	319

Plans with accumulated benefit obligations in excess of plan assets consist of the following:


	Retirement Plans
(Dollars in Millions)	2007			2006
Accumulated benefit obligation	$	(4,914	)		(3,085	)
Projected benefit obligation		(5,233	)		(3,561	)
Plan assets at fair value		3,735			1,650


62		JOHNSON & JOHNSON 2007 ANNUAL REPORT

Strategic asset allocations are determined by country, based on the nature of the liabilities and considering the demographic composition of the plan participants (average age, years of service and active versus retiree status). The Company’s plans are considered non-mature plans and the long-term strategic asset allocations are consistent with these types of plans. Emphasis is placed on diversifying equities on a broad basis combined with currency matching of the fixed income assets.

The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans:


(Dollars in Millions)	2008			2009			2010			2011			2012			2013-2017
Projected future benefit payments

Retirement plans	$	457			472			507			542			564			3,467

Other benefit plans — gross	$	274			180			184			188			192			1,080
Medicare rebates		(9	)		(11	)		(12	)		(13	)		(14	)		(94	)

Other benefit plans — net	$	265		$	169		$	172		$	175		$	178		$	986

The Company was not required to fund its U.S. retirement plans in 2007 and is not required, nor does it anticipate funding in 2008 to meet minimum statutory funding requirements. International plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. In certain countries other than the United States, the funding of pension plans is not a common practice as funding provides no economic benefit. Consequently the Company has several pension plans which are not funded.

The following table displays the projected future minimum contributions to the Company’s U.S. and international unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.


(Dollars in Millions)	2008		2009		2010		2011		2012		2013-2017
Projected future contributions

Unfunded U.S. retirement plans	$	28		30		33		35		38		238

Unfunded International retirement plans	$	23		25		28		29		31		178

The Company’s retirement plan asset allocation at the end of 2007 and 2006 and target allocations for 2008 are as follows:


	Percent of						Target
	Plan Assets						Allocation
	2007			2006			2008
U.S. Retirement Plans

Equity securities		79	%		78	%		75	%
Debt securities		21			22			25

Total plan assets		100	%		100	%		100	%


International Retirement Plans

Equity securities		67	%		67	%		67	%
Debt securities		32			32			33
Real estate and other		1			1			—

Total plan assets		100	%		100	%		100	%

The Company’s other benefit plans are unfunded except for U.S. life insurance contract assets of $29 million and $30 million at December 30, 2007 and December 31, 2006, respectively.

The fair value of Johnson & Johnson common stock directly held in plan assets was $462 million (4.4% of total plan assets) at December 30, 2007 and $452 million (4.9% of total plan assets) at December 31, 2006.


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		63

14. Cash, Cash Equivalents and Marketable Securities


	December 30, 2007						December 31, 2006
	Amortized		Unrealized		Estimated		Amortized		Unrealized		Estimated
(Dollars in Millions)	Cost		Gains/(Losses)		Fair Value		Cost		Gains/(Losses)		Fair Value
Current Investments

Cash	$	2,978		—		2,978		1,909		—		1,909
Government securities and obligations		2,722		1		2,723		—		—		—
Corporate debt securities		1,805		3		1,808		—		—		—
Money market funds		407		—		407		1,116		—		1,116
Time deposits		1,403		—		1,403		1,059		—		1,059

Total cash, cash equivalents and current marketable securities	$	9,315		4		9,319		4,084		—		4,084


Non-Current Investments

Marketable securities	$	2		—		2		16		—		16

15. Financial Instruments

The Company follows the provisions of SFAS No. 133 requiring that all derivative instruments be recorded on the balance sheet at fair value.

As of December 30, 2007, the balance of deferred net losses on derivatives included in accumulated other comprehensive income was $45 million after-tax. For additional information, see Note 12. The Company expects that substantially all of this amount will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months. The amount ultimately realized in earnings will differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. Derivative gains/(losses), initially reported as a component of other comprehensive income, are reclassified to earnings in the period when the forecasted transactions affect earnings.

For the years ended December 30, 2007, December 31, 2006 and January 1, 2006, the net impact of hedge ineffectiveness, transactions not qualifying for hedge accounting and discontinuance of hedges, to the Company’s financial statements was insignificant.

Refer to Note 12 for disclosures of movements in Accumulated Other Comprehensive Income.

CONCENTRATION OF CREDIT RISK

The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an A
(or equivalent) credit rating. On average these investments mature within six months, and the Company has not incurred any related losses.

16. Savings Plan

The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $169 million in 2007, $158 million in 2006 and $148 million in 2005.

17. Mergers, Acquisitions and Divestitures

Certain businesses were acquired for $1,388 million in cash and $232 million of liabilities assumed during 2007. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.

The 2007 acquisitions included: Conor Medsystems, Inc., a cardiovascular device company, with new drug delivery technology; Robert Reid, Inc., a Japanese orthopedic product distributor and Maya’s Mom, Inc., a social media company.

The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $636 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $807 million has been identified as the value of IPR&D associated with the acquisition of Conor Medsystems, Inc.

The IPR&D charge related to the acquisition of Conor Medsystems, Inc. was $807 million and is associated with research related to the discovery and application of the stent technology. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 19%.

Certain businesses were acquired for $18.0 billion in cash and $1.3 billion of liabilities assumed during 2006. These acquisitions were accounted for by the purchase method and, accordingly, results of Operations have been included in the financial statements from their respective dates of acquisition except as noted below.

On December 20, 2006, the Company completed the acquisition of the Consumer Healthcare business of Pfizer Inc. for a purchase price of $16.6 billion in cash. The operating results of the Consumer Healthcare business of Pfizer Inc. were reported in the Company’s financial statements beginning in 2007, as 2006 results subsequent to the acquisition date were not significant.

In order to obtain regulatory approval of the transaction, the Company agreed to divest certain overlapping businesses. The Company completed the divestiture of the ZANTAC^® product on December 20, 2006 and the divestitures of KAOPECTATE^®, UNISOM^®, CORTIZONE ^®, BALMEX ^® and ACT^® products on January 2, 2007.

The following table provides pro forma results of operations for the fiscal year ended January 1, 2006 and the fiscal year ended December 31, 2006, as if the Consumer Healthcare business of Pfizer Inc. had been acquired as of the beginning of each


64		JOHNSON & JOHNSON 2007 ANNUAL REPORT

period presented. The pro forma results include the effect of divestitures and certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of the Consumer Healthcare business of Pfizer Inc. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future.


(Unaudited)	Pro forma results
	Year ended		Year ended
	December 31,		January 1,
(Dollars in Millions Except Per Share Data)	2006		2006
Net sales	$	57,115		54,156
Net earnings		10,770		9,784
Diluted net earnings per share	$	3.64		3.26

During 2007, the Company completed the allocation of the purchase price to the individual assets acquired and liabilities assumed. The following table presents the completed allocation of the purchase price for the Consumer Healthcare business of Pfizer Inc. as of the date of the acquisition.


(Dollars in Millions)

Current assets	$	2,250
Property, plant and equipment		552
Deferred tax asset		499
Goodwill		6,547
Intangible assets		8,585

Total assets acquired	$	18,433

Current liabilities		1,095
Non-current liabilities		1,061

Total liabilities assumed	$	2,156

Net assets acquired	$	16,277

The acquisition of the Consumer Healthcare business of Pfizer Inc. resulted in $6.5 billion in goodwill, which is allocated to the Consumer segment.

The purchase price allocation to the identifiable intangible assets before the effect of any amortization included in the current period balance sheet is as follows:


(Dollars in Millions)

Intangible assets with determinable lives:
Brands	$	302
Patents and technology		321
Customer relationships		3,067

Total amortizable intangibles		3,690
Brands with indefinite lives		4,895

Total intangible assets	$	8,585

The weighted average life of the $3,690 million of total amortizable intangibles is approximately 31 years from the date of acquisition.

The majority of the intangible asset valuation relates to brands. The assessment as to brands that have an indefinite life and those that have a determinable life was based on a number of factors, including the competitive environment, market share, brand history, product life cycles, operating plan and the macro-economic environment of the countries in which the brands are sold. The brands that account for over 90% of the total value of all indefinite-life brands include LISTERINE ^®, NICORETTE ^®, NEOSPORIN^®, SUDAFED^®, BENADRYL^®, VISINE ^® and BENYLIN^®. The determinable-life brands include PURELL^®, ACTIFED^®, EFFERDENT^® and other regional or country specific brands. The determinable-life brands have asset lives ranging from 5 to 40 years. The patents and technology intangibles are concentrated in the upper respiratory, oral care, medicated skin care, tobacco dependence and hair growth businesses and have asset lives ranging from 5 to 20 years. The estimated customer relationship intangible asset useful lives, ranging from 30 to 40 years, reflect the very low historical and projected customer attrition rates among the Consumer Healthcare business of Pfizer Inc.’s major retailer and distributor customers.

The IPR&D charge related to the acquisition of the Consumer Healthcare business of Pfizer Inc. was $320 million on a pre-tax basis and $217 million on an after-tax basis and is primarily associated with rights obtained to the switch of ZYRTEC^® from U.S. prescription to over-the-counter status. The switch was approved by the FDA effective November 2007. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 95% was used to reflect inherent regulatory risk as of the acquisition date and the discount rate applied was 11%.

The Company completed the analysis of integration plans, pursuant to which the Company is incurring costs primarily related to the elimination of certain duplicate selling, general and administrative functions between the two companies in areas such as global business services, corporate staff and go-to-market support, as well as excess manufacturing capacity.

In addition to the acquisition of the Consumer Healthcare business of Pfizer Inc., 2006 acquisitions included: Animas Corporation, a leading maker of insulin infusion pumps and related products; Hand Innovations LLC, a privately held manufacturer of fracture fixation products for the upper extremities; Future Medical Systems S.A., a privately held company that primarily develops, manufactures and markets arthroscopic fluid management systems; Vascular Control Systems, Inc., a privately held company focused on developing medical devices to treat fibroids and to control bleeding in obstetric and gynecologic applications; Group Vendôme S.A., a privately held French marketer of adult and baby skin care products; ColBar Lifescience Ltd., a privately held company specializing in reconstructive medicine and tissue engineering and Ensure Medical, Inc., a privately held company that develops devices for post-catheterization closure of the femoral artery.

Excluding the acquisition of the Consumer Healthcare business of Pfizer Inc., the excess of purchase price over the estimated fair value of tangible assets acquired in 2006 amounted to $1,209 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $239 million has been identified as the value of IPR&D primarily associated with the acquisitions of Hand Innovations LLC, Future Medical Systems S.A., Vascular Control Systems, Inc., ColBar Lifescience Ltd. and Ensure Medical, Inc.

The IPR&D charge related to the acquisition of Hand Innovations LLC was $22 million and is associated with fracture


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		65

repair technologies. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 38–95% were used to reflect inherent clinical and regulatory risk and the discount rate applied was 17%.

The IPR&D charge related to the acquisition of Future Medical Systems S.A. was $15 million and is associated with the NEXTRA and DUO PUMP product technologies. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 90% for both technologies was used to reflect inherent clinical and regulatory risk and the discount rate applied was 22%.

The IPR&D charge related to the acquisition of Vascular Control Systems, Inc. was $87 million and is associated with the FLOSTAT system technology. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 75% was used to reflect inherent clinical and regulatory risk and the discount rate applied was 21%.

The IPR&D charge related to the acquisition of ColBar Lifescience Ltd. was $49 million and is associated with the EVOLENCE^® family of products, which are biodegradable dermal fillers. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. Probability of success factors ranging from 70 – 80% were used to reflect inherent clinical and regulatory risk and the discount rate applied was 21%.

The IPR&D charge related to the acquisition of Ensure Medical, Inc. was $66 million and is associated with the femoral artery closure device. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 75% was used to reflect inherent clinical and regulatory risk and the discount rate applied was 22%.

Certain businesses were acquired for $987 million in cash and $141 million of liabilities assumed during 2005. These acquisitions were accounted for by the purchase method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.

The 2005 acquisitions included: TransForm Pharmaceuticals, Inc., a company specializing in the discovery of superior formulations and novel crystalline forms of drug molecules; Closure Medical Corporation, a company with expertise and intellectual property in the biosurgicals market; Peninsula Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections; and rights to all consumer and professionally dispensed REMBRANDT^® Brand of oral care products, such as whitening toothpastes, strips, systems and mouth rinses.

The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $720 million and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Approximately $362 million has been identified as the value of IPR&D primarily associated with the acquisitions of TransForm Pharmaceuticals, Inc., Closure Medical Corporation and Peninsula Pharmaceuticals, Inc.

The IPR&D charge related to the acquisition of TransForm Pharmaceuticals Inc. was $50 million and is associated with research related to the discovery and application of superior formulations. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 10%.

The IPR&D charge related to the acquisition of Closure Medical Corporation was $51 million and is as associated with the OMNEX™ Surgical Sealant in vascular indications outside Europe and in other potential indications worldwide. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 90% for vascular indications and 60% for all other indications was used to reflect inherent clinical and regulatory risk. The discount rate applied to both vascular and other indications was 15%.

The IPR&D charge related to the acquisition of Peninsula Pharmaceuticals, Inc. was $252 million and is associated with the development of doripenem, which is in Phase III clinical trials. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. A probability of success factor of 80% was used to reflect inherent clinical and regulatory risk and the discount rate applied was 14%.

The remaining $9 million in IPR&D was associated with the acquisition of international commercial rights to certain patents and know-how in the field of sedation and analgesia from Scott Lab, Inc. The value of the IPR&D was calculated using cash flow projections discounted for the risk inherent in such projects. The discount rate was 17%.

With the exception of the Consumer Health care business Pfizer Inc., supplemental pro forma information for 2007, 2006 and 2005 per SFAS No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets, is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations, cash flows or financial position.

Divestitures in 2007, 2006 and 2005 did not have a material effect on the Company’s results of operations, cash flows or financial position.

18. Legal Proceedings

PRODUCT LIABILITY

The Company is involved in numerous product liability cases in the United States, many of which concern adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use that accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any liability results from such cases, it will be substantially covered by existing amounts accrued in the Company’s balance sheet and, where available, by third-party product liability insurance.


66		JOHNSON & JOHNSON 2007 ANNUAL REPORT

Multiple products of Johnson & Johnson subsidiaries are subject to numerous product liability claims and lawsuits, including ORTHO EVRA^®, RISPERDAL^®, DURAGESIC^® and the CHARITÉ™ Artificial Disc. There are approximately 4,000 claimants who have filed lawsuits or made claims regarding injuries allegedly due to ORTHO EVRA^®, 613 claimants with respect to RISPERDAL^®, 260 with respect to CHARITÉ™ and 49 with respect to DURAGESIC^®. These claimants seek substantial compensatory and, where available, punitive damages.

With respect to RISPERDAL^®, the Attorneys General of five states and the Office of General Counsel of the Commonwealth of Pennsylvania have filed actions seeking reimbursement of Medicaid or other public funds for RISPERDAL^® prescriptions written for off-label use, compensation for treating their citizens for alleged adverse reactions to RISPERDAL^®, civil fines or penalties, punitive damages, or other relief. The Attorney General of Texas has joined a qui tam action in that state seeking similar relief. Certain of these actions also seek injunctive relief relating to the promotion of RISPERDAL^®. The Attorneys General of a number of other states have indicated a potential interest in pursuing similar litigation against the company’s Janssen subsidiary, and have obtained a tolling agreement staying the running of the statute of limitations while they inquire into the issues. In addition, there are six cases filed by union health plans seeking damages for alleged overpayments for RISPERDAL^®, several of which seek certification as class actions.

Numerous claims and lawsuits in the United States relating to the drug PROPULSID^®, withdrawn from general sale by the Company’s Janssen subsidiary in 2000, have been resolved or are currently enrolled in settlement programs with an aggregate cap below $100 million. Litigation concerning PROPULSID^® is pending in Canada, where a class action of persons alleging adverse reactions to the drug has been certified.

AFFIRMATIVE STENT PATENT LITIGATION

In patent infringement actions tried in Delaware Federal District Court in late 2000, Cordis Corporation (Cordis), a subsidiary of Johnson & Johnson, obtained verdicts of infringement and patent validity, and damage awards against Boston Scientific Corporation (Boston Scientific) and Medtronic AVE, Inc. (Medtronic) based on a number of Cordis vascular stent patents. In December 2000, the jury in the damage action against Boston Scientific returned a verdict of $324 million and the jury in the Medtronic action returned a verdict of $271 million. The Court of Appeals for the Federal Circuit recently upheld liability in these cases and returned the cases to the District Court for further proceedings, including on damages.

Cordis also has an arbitration claim against Medtronic accusing Medtronic of infringement by sale of stent products introduced by Medtronic subsequent to its products subject to the earlier action referenced above. Those subsequent products were found to have been licensed to Medtronic pursuant to a 1997 license by an arbitration panel in March 2005. Further arbitration proceedings will determine whether royalties are owed for those products.

In January 2003, Cordis filed a patent infringement action against Boston Scientific in Delaware Federal District Court accusing its Express2™, Taxus^® and Liberte^® stents of infringing the Palmaz patent that expired in November 2005. The Liberte^® stent was also accused of infringing Cordis’ Gray patent that expires in 2016. In June 2005, a jury found that the Express2™, Taxus^® and Liberte^® stents infringed the Palmaz patent and that the Liberte^® stent also infringed the Gray patent. Boston Scientific has appealed to the U.S. Court of Appeals for the Federal Circuit.

PATENT LITIGATION AGAINST VARIOUS
JOHNSON & JOHNSON SUBSIDIARIES

The products of various Johnson & Johnson subsidiaries are the subject of various patent lawsuits, the outcomes of which could potentially adversely affect the ability of those subsidiaries to sell those products, or require the payment of past damages and future royalties.

In July 2005, a jury in Federal District Court in Delaware found that the Cordis CYPHER^® Stent infringed Boston Scientific’s Ding ’536 patent and that the Cordis CYPHER^® and BX VELOCITY^® Stents also infringed Boston Scientific’s Jang ’021 patent. The jury also found both of those patents valid. Boston Scientific seeks substantial damages and an injunction in that action. The District Court denied motions by Cordis to overturn the jury verdicts or grant a new trial. Cordis has appealed to the Court of Appeals for the Federal Circuit. The District Court indicated it will consider damages, willfulness and injunctive relief after the appeals have been decided.

Boston Scientific has brought actions in Belgium, the Netherlands, Germany and France under its Kastenhofer patent, which purports to cover two-layer catheters such as those used to deliver the CYPHER^® Stent, to enjoin the manufacture and sale of allegedly infringing catheters in those countries, and to recover damages. A hearing in the Belgian case is scheduled for May 2008. A decision by the lower court in the Netherlands in Boston Scientific’s favor was reversed on appeal in April 2007. Boston Scientific has filed an appeal to the Dutch Supreme Court. In October 2007, Boston Scientific prevailed in the nullity action challenging the validity of the Kastenhofer patent filed by Cordis in Germany. Cordis intends to appeal. No hearings have been scheduled in the French action.

Trial in Boston Scientific’s U.S. case based on the Kastenhofer patent concluded in Federal Court in California in October 2007, with a jury verdict in favor of Cordis. The jury found the Kastenhofer patent invalid and found for Cordis with respect to infringement of the patent asserted by Cordis in its counterclaim. Post trial motions and appeals are anticipated.

In Germany, Boston Scientific has several actions based on its Ding patents pending against the Cordis CYPHER^® Stent. Cordis was successful in these actions at the trial level, but Boston Scientific has appealed.



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		67

The following chart summarizes various patent lawsuits concerning products of Johnson & Johnson subsidiaries that have yet to proceed to trial:

J&J

Plaintiff/

Product

Company

Patents

Patent Holder

Court

Trial Date

Date Filed

Two-layer
Catheters

Cordis

Kasten-
hofer
Forman

Boston Scientific Corp.

Multiple European

09/07

Contact Lenses

Vision Care

Nicolson

CIBA Vision

M.D. FL Multiple European

*
*

09/03
09/07

Stents

Cordis

Ricci

Medtronic and Evysio

E.D. TX

03/07

CYPHER^® Stent

Cordis

Wall

E.D. TX

11/07

CYPHER^® Stent

Cordis

Bonutti

MarcTec

S.D. IL

11/07

CYPHER^® Stent

Cordis

Saffran

E.D. TX

10/07


*		Trial date to be established.

LITIGATION AGAINST FILERS OF ABBREVIATED NEW DRUG APPLICATIONS (ANDA)

The following chart indicates lawsuits pending against generic firms that filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of these patents. In the event the subsidiary of the Company involved is not successful in these actions, or the statutory 30-month stay expires before a ruling from the district court is obtained, the firms involved will have the ability, upon FDA approval, to introduce generic versions of the product at issue resulting in very substantial market share and revenue losses for the product of the Company’s subsidiary.

As noted in the following chart, 30-month stays expired during 2006 and 2007, and will expire in 2008, 2009 and 2010 with respect to ANDA challenges regarding various products:

Brand Name

Patent/NDA

Generic

Trial

Date

30-Month

Product

Holder

Challenger

Court

Date

Filed

Stay Expiration

ACIPHEX^®
20 mg delay
release tablet

Eisai
(for Janssen)

Teva Dr. Reddy’s

S.D. NY
S.D. NY

03/07
03/07

11/03
11/03

02/07
02/07

CONCERTA^®
18, 27, 36 and 54 mg
controlled release tablet

McNeil-PPC
ALZA

Andrx

D. DE

12/07

09/05

None

LEVAQUIN^®
250, 500, 750 mg tablets

Ortho-McNeil

Lupin

D. NJ

10/06

03/09

ORTHO TRI CYCLEN ^® LO
0.18 mg/0.025 mg
0.215 mg/0.025 mg
and 0.25 mg/0.025 mg

Ortho-McNeil

Barr

D. NJ

10/03

02/06

PEPCID COMPLETE^®

McNeil-PPC

Perrigo

S.D. NY

02/07

02/05

06/07

RAZADYNE™

Janssen

Teva

D. DE

05/07

07/05

08/08

Mylan

D. DE

05/07

07/05

08/08

Dr. Reddy’s

D. DE

05/07

07/05

08/08

Purepac

D. DE

05/07

07/05

08/08

Barr

D. DE

05/07

07/05

08/08

Par

D. DE

05/07

07/05

08/08

AlphaPharm

D. DE

05/07

07/05

08/08

RAZADYNE™ ER

Janssen

Barr

D. NJ

06/06

11/08

Sandoz

D. NJ

05/07

12/08

KV Pharma

D. NJ

12/07

05/10



68		JOHNSON & JOHNSON 2007 ANNUAL REPORT

Brand Name

Patent/NDA

Generic

Trial

Date

30-Month

Product

Holder

Challenger

Court

Date

Filed

Stay Expiration

RISPERDAL^® Oral
Solution, 1 mg/ml

Janssen

Apotex

D. NJ

03/06

08/08

TOPAMAX^®
25, 50, 100, 200 mg tablet

Ortho-McNeil

Mylan
Cobalt

D. NJ
D. NJ

*
*

04/04
10/05

09/06
03/08

TOPAMAX^® SPRINKLE
15, 25 mg capsule

Ortho-McNeil

Cobalt
Mylan

D. NJ
D. NJ

*
*

12/05
10/06

05/08
03/09

ULTRACET

Ortho-McNeil

Apotex

N.D. IL

07/07

12/09

ULTRAM ER^®
100, 200, 300 mg tablet

Ortho-McNeil

Par

D. DE

11/08

05/07

09/09


*		Trial date to be established.

Trial in the action against Teva, Dr. Reddy’s and Mylan with respect to their ANDA challenges to the patent on ACIPHEX^® of Eisai Inc., the Company’s subsidiary Ortho-McNeil Pharmaceutical, Inc.’s (Ortho-McNeil) marketing partner, proceeded before the District Court in New York in March 2007. In May 2007, the Court held that the ACIPHEX^® compound patent is enforceable. The Court had previously held that the patent is valid. Teva and Dr. Reddy’s have appealed both decisions to the Court of Appeals for the Federal Circuit. Mylan withdrew its appeal.

In the action against Apotex regarding RISPERDAL^® (risperidone) Oral Solution, the trial court dismissed Apotex’s challenge to the validity and infringement of two patents relating to formulations for an oral solution product. Apotex appealed this decision in October 2007.

In the actions against Mylan with respect to the patent on TOPAMAX^®, the District Court in New Jersey, in 2006, granted the motion of Ortho-McNeil for a preliminary injunction barring launch by Mylan of its generic versions of TOPAMAX^®. In February 2007, the District Court granted Ortho-McNeil’s motion for summary judgment dismissing Mylan’s claim that the patent was obvious, the only remaining issue in the case. The Court entered judgment in the case for Ortho-McNeil, and entered an injunction prohibiting Mylan from marketing its generic topiramate products until a date no earlier than patent expiration in September 2008. Mylan has appealed this ruling. In April 2007, the District Court entered judgment against Cobalt pursuant to its stipulation to be bound by the outcome in the Mylan suit. Cobalt appealed this ruling. The Court of Appeals heard argument on both appeals in November 2007. A ruling is expected in the near term.

In the action against Perrigo regarding a patent for PEPCID COMPLETE^®, the District Court for the Southern District of New York, in June 2007, held that the patent was invalid as obvious. The Company’s subsidiary McNEIL-PPC, Inc. has appealed the decision with its partners, Merck & Co., Inc., and Johnson & Johnson*Merck Consumer Pharmaceuticals Co.

In the action against Barr and AlphaPharm with respect to their ANDA challenges to the RAZADYNE^® patent that Janssen licenses from Synaptech, Inc., a four-day non-jury trial was held in the District Court in Delaware in May 2007. The Court has yet to issue its ruling in that action.

In the action against Andrx with respect to its ANDA challenge to the CONCERTA^® patents, a five-day non-jury trial was held in the District Court in Delaware in December 2007. The Court has yet to issue its ruling in that action.

In the action against Sandoz with respect to its ANDA challenge to a RAZADYNE^® ER patent that Janssen licenses from Synaptech, Inc., the action has been stayed pending the outcome in the above litigation in Delaware federal court. Sandoz has challenged only one of two patents for RAZADYNE^® ER, and has certified that it will await expiration of the second patent in 2019 before marketing its generic version of RAZADYNE^® ER.

In the action against Teva with respect to its ANDA challenge to an AXERT^® patent that Janssen licenses from Almirall Prodesfarma, S.A., the parties settled their dispute and the court entered a consent judgment in January 2008.

In the weeks following the adverse ruling in the DITROPAN XL^® ANDA litigation against Mylan in September 2005, Johnson & Johnson and ALZA received seven antitrust class action complaints filed by purchasers of the product. They allege that Johnson & Johnson and ALZA violated federal and state antitrust laws by knowingly pursuing baseless patent litigation, and thereby delaying entry into the market by Mylan and Impax. In late 2007, plaintiffs in all these cases dismissed their claims with prejudice.

AVERAGE WHOLESALE PRICE (AWP) LITIGATION

Johnson & Johnson and several of its pharmaceutical subsidiaries, along with numerous other pharmaceutical companies, are defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Most of these cases, both federal actions and state actions removed to federal court, have been consolidated for pre-trial purposes in a Multi-District Litigation (MDL) in Federal District Court in Boston, Massachusetts. The plaintiffs in these cases include classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP.

The MDL Court identified classes of Massachusetts-only private insurers providing “Medi-gap” insurance coverage and private payers for physician-administered drugs where payments were based on AWP (“Class 2” and “Class 3”), and a national class of individuals who made co-payments for physician-administered drugs covered by Medicare (“Class 1”). A trial of the two Massachusetts-only class actions concluded before the MDL Court in December 2006. In June 2007, the MDL Court issued post-trial rulings, dismissing the Johnson & Johnson defendants from the case regarding all claims of Classes 2 and 3, and subsequently of Class 1 as well. Trial in the action brought by



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		69

the Attorney General of the State of Alabama making allegations related to AWP is expected to proceed during 2008. Additional AWP cases brought by various Attorneys General are expected to be set for trial in 2008.

OTHER

In July 2003, Centocor Inc., a Johnson & Johnson subsidiary received a request that it voluntarily provide documents and information to the criminal division of the U.S. Attorney’s Office, District of New Jersey, in connection with its investigation into various Centocor marketing practices. Subsequent requests for documents have been received from the U.S. Attorney’s Office. Both the Company and Centocor responded, or are in the process of responding, to these requests for documents and information.

In December 2003, Ortho-McNeil received a subpoena from the U.S. Attorney’s Office in Boston, Massachusetts seeking documents relating to the marketing, including alleged off-label marketing, of the drug TOPAMAX^® (topiramate). Additional subpoenas for documents have been received. Ortho-McNeil is cooperating in responding to the subpoenas. In October 2004, the U.S. Attorney’s Office in Boston asked attorneys for Ortho-McNeil to cooperate in facilitating the subpoenaed testimony of several present and former Ortho-McNeil employees before a federal grand jury in Boston. Cooperation in securing the testimony of additional witnesses before the grand jury has been requested and is being provided.

In January 2004, Janssen received a subpoena from the Office of the Inspector General of the U.S. Office of Personnel Management seeking documents concerning sales and marketing of, any and all payments to physicians in connection with sales and marketing of, and clinical trials for, RISPERDAL^® (risperidone) from 1997 to 2002. Documents subsequent to 2002 have also been requested. An additional subpoena seeking information about marketing of and adverse reactions to RISPERDAL^® was received from the U.S. Attorney’s Office for the Eastern District of Pennsylvania in November 2005. Subpoenas seeking testimony from various witnesses before a grand jury have also been received. Janssen is cooperating in responding to these subpoenas.

In August 2004, Johnson & Johnson Health Care Systems, Inc. (HCS), a Johnson & Johnson subsidiary, received a subpoena from the Dallas, Texas U.S. Attorney’s Office seeking documents relating to the relationships between the group purchasing organization, Novation, and HCS and other Johnson & Johnson subsidiaries. The Company’s subsidiaries involved have responded to the subpoena.

In September 2004, Ortho Biotech Inc. (Ortho Biotech), received a subpoena from the U.S. Office of Inspector General’s Denver, Colorado field office seeking documents directed to sales and marketing of PROCRIT^® (Epoetin alfa) from 1997 to the present, as well as to dealings with U.S. Oncology Inc., a healthcare services network for oncologists. Ortho Biotech has responded to the subpoena.

In September 2004, plaintiffs in an employment discrimination litigation initiated against the Company in 2001 in Federal District Court in New Jersey moved to certify a class of all African American and Hispanic salaried employees of the Company and its affiliates in the U.S., who were employed at any time from November 1997 to the present. Plaintiffs seek monetary damages for the period 1997 through the present (including punitive damages) and equitable relief. The Court denied plaintiffs’ class certification motion in December 2006 and their motion for reconsideration in April 2007. Plaintiffs are seeking to appeal these decisions.

In March 2005, DePuy Orthopaedics, Inc. (DePuy), a Johnson & Johnson subsidiary, received a subpoena from the U.S. Attorney’s Office, District of New Jersey, seeking records concerning contractual relationships between DePuy and surgeons or surgeons-in-training involved in hip and knee replacement and reconstructive surgery. This investigation was resolved by DePuy and the four other leading suppliers of hip and knee implants in late September 2007 by agreements with the U.S. Attorney’s Office for the District of New Jersey. The settlements include an 18-month Deferred Prosecution Agreement (DPA), acceptance by each company of a monitor to assure compliance with the DPA and, with respect to four of the five companies, payment of settlement monies and entry into five year Corporate Integrity Agreements. DePuy paid $85 million as its settlement. In November 2007, the Attorney General of the Commonwealth of Massachusetts issued a civil investigative demand to DePuy seeking information regarding financial relationships between a number of Massachusetts-based orthopedic surgeons and providers and DePuy, which relationships had been publicly disclosed by DePuy pursuant to the DPA. In February 2008, DePuy received a written request for information from the United States Senate Special Committee on Aging, as a follow-up to earlier inquiries, concerning a number of aspects of the DPA. Depuy is responding to both requests.

In June 2005, the U.S. Senate Committee on Finance requested the Company to produce information regarding use by several of its pharmaceutical subsidiaries of educational grants. A similar request was sent to other major pharmaceutical companies. In July 2005, the Committee specifically requested information about educational grants in connection with the drug PROPULSID^®. A follow up request was received from the Committee for additional information in January 2006. On October 30, 2007 another letter was received from the U.S. Senate Committee on Finance requesting information concerning payments to a list of physicians, and specification as to whether any such payments were for continuing medical education, honoraria, research support, etc.

In July 2005, Scios Inc. (Scios), a Johnson & Johnson subsidiary, received a subpoena from the U.S. Attorney’s Office, District of Massachusetts, seeking documents related to the sales and marketing of NATRECOR^®. Scios is responding to the subpoena. In early August 2005, Scios was advised that the investigation would be handled by the U.S. Attorney’s Office for the Northern District of California in San Francisco.

In September 2005, Johnson & Johnson received a subpoena from the U.S. Attorney’s Office, District of Massachusetts, seeking documents related to sales and marketing of eight drugs to Omnicare, Inc., a manager of pharmaceutical benefits for long-term care facilities. The Johnson & Johnson subsidiaries involved are responding to the subpoena. Several employees of the Company’s pharmaceutical subsidiaries have been subpoenaed to testify before a grand jury in connection with this investigation.

In November 2005, Amgen filed suit against Hoffmann-LaRoche, Inc. in the U.S. District Court for the District of Massachusetts seeking a declaration that the Roche product CERA, which Roche has indicated it will seek to introduce into



70		JOHNSON & JOHNSON 2007 ANNUAL REPORT

the United States, infringes a number of Amgen patents concerning EPO. Amgen licenses EPO for sale in the United States to Ortho Biotech for non-dialysis indications. Trial in this action concluded in October with a verdict in Amgen’s favor. Roche is expected to appeal.

In late December 2005 and early 2006, three purported class actions were filed on behalf of purchasers of endo-mechanical instruments against the Company and its wholly-owned subsidiaries, Ethicon, Inc., Ethicon Endo-Surgery, Inc., and Johnson & Johnson Health Care Systems, Inc. These challenge suture and endo-mechanical contracts with Group Purchasing Organizations and hospitals, in which discounts are predicated on a hospital achieving specified market share targets for both categories of products. These actions have been filed in the Federal District Court for the Central District of California.

In February 2006, Johnson & Johnson received a subpoena from the U.S. Securities & Exchange Commission (SEC) requesting documents relating to the participation by several Johnson & Johnson subsidiaries in the United Nations Iraq Oil for Food Program. The subsidiaries are cooperating with the SEC and U.S. Department of Justice (DOJ) in producing responsive documents.

In June 2006, DePuy received a subpoena from the DOJ’s Antitrust Division, requesting documents related to the manufacture, marketing and sale of orthopaedic devices, and had search warrants executed in connection with the investigation. DePuy has responded to the request for documents. In the wake of publicity about the subpoena, DePuy was served with five civil antitrust class actions. All of those cases have been dismissed without prejudice to the right to file them in the future.

In September 2006, Janssen received a subpoena from the Attorney General of the State of California seeking documents regarding sales and marketing and side-effects of RISPERDAL^®, as well as interactions with State officials regarding the State’s formulary for Medicaid-reimbursed drugs. Janssen has responded to the subpoena.

In November 2006, Centocor received a subpoena seeking documents in connection with an investigation being conducted by the Office of the United States Attorney for the Central District of California regarding Centocor’s Average Selling Price (ASP) calculations for REMICADE^® under the company’s Contract Purchase Program. Centocor produced material responsive to the subpoena. Centocor has been advised that this investigation has been closed.

In February 2007, Johnson & Johnson voluntarily disclosed to the DOJ and the SEC that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries, which payments may fall within the jurisdiction of the Foreign Corrupt Practices Act (FCPA). In the course of continuing dialogues with the agencies, other issues potentially rising to the level of FCPA violations in additional markets have been brought to the attention of the agencies by the Company. The Company has provided and will continue to provide additional information to DOJ and SEC, and will cooperate with the agencies’ reviews of these matters.

In March 2007, Cordis received a letter request for documents from the Committee on Oversight and Government Reform of the U.S. House of Representatives regarding marketing and safety of drug-eluting stents. Cordis is cooperating in responding to the request.

In March 2007, the Company received separate subpoenas from the U.S. Attorney’s Office in Philadelphia, the U.S. Attorney’s Office in Boston and the U.S. Attorney’s Office in San Francisco. The subpoenas relate to investigations by these three offices referenced above concerning, respectively, sales and marketing of RISPERDAL^® by Janssen, TOPAMAX^® by Ortho-McNeil and NATRECOR^® by Scios. The subpoenas request information regarding the Company’s corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs. The Company is cooperating in responding to these requests. In addition, the U.S. Attorney’s office in Boston has issued subpoenas to several employees of Johnson & Johnson.

In March 2007, the Company received a letter from the Committee on Energy and Commerce of the U.S. House of Representatives seeking answers to several questions regarding marketing and safety of PROCRIT^®, the erythropoietin product sold by Ortho-Biotech. In May 2007, Senator Grassley, the ranking member of the United States Senate Committee on Finance, sent the Company a letter seeking information relating to PROCRIT^®. The Company provided its initial response in July 2007. In May 2007, the New York State Attorney General issued a subpoena seeking information relating to PROCRIT^®. Like the House and Senate requests, the subpoena asks for materials relating to PROCRIT^® safety, marketing and pricing. The Company is responding to these requests.

In April 2007, the Company received two subpoenas from the Office of the Attorney General of the State of Delaware. The subpoenas seek documents and information relating to nominal pricing agreements. For purposes of the subpoenas, nominal pricing agreements are defined as agreements under which the Company agreed to provide a pharmaceutical product for less than ten percent of the Average Manufacturer Price for the product. The Company is responding to the subpoenas and will cooperate with the inquiry.

In August 2007, the Company received a request for documents and interviews of witnesses from the Committee on Energy and Commerce of the U.S. House of Representatives concerning GMP (Good Manufacturing Practice) issues involving the CYPHER^® Stent. The letter states that FDA inspectors in 2003 identified “numerous systemic violations” of GMP’s in connection with CYPHER^® manufacturing but nonetheless allowed Cordis to continue marketing CYPHER^® Stents. Cordis is cooperating in responding to this request.

In October 2007, the Company received a request for documents from Senator Grassley on behalf of the Committee on Finance of the U.S. Senate concerning continuing medical education payments to specific physicians. The Company is in the process of complying with the request.

In December 2007, the Company and its subsidiary Janssen received a request from Senator Grassley on behalf of the Committee on Finance of the U.S. Senate for documents and information concerning the marketing and promotion of RISPERDAL^® for use by nursing home patients. The companies are in the process of collecting responsive documents and obtaining the relevant information.

With respect to all the above matters, the Company and its subsidiaries are vigorously contesting the allegations asserted against them and otherwise pursuing defenses to maximize the prospect of success. The Company and its subsidiaries involved in these matters continually evaluate their strategies in managing these matters and, where appropriate, pursue settlements



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		71

and other resolutions where those are in the best interest of the Company.

The Company is also involved in a number of other patent, trademark and other lawsuits incidental to its business. The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company’s results of operations and cash flows for that period.

19. Earnings Per Share

The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 30, 2007, December 31, 2006 and January 1, 2006:


(Shares in Millions Except Per Share Data)	2007			2006			2005

Basic net earnings per share	$	3.67			3.76			3.38
Average shares outstanding — basic		2,882.9			2,936.4			2,973.9
Potential shares exercisable under stock option plans		178.6			207.0			203.1
Less: shares repurchased under treasury stock method		(154.5	)		(186.3	)		(178.6	)
Convertible debt shares		3.7			3.9			4.4

Adjusted average shares outstanding — diluted		2,910.7			2,961.0			3,002.8
Diluted net earnings per share	$	3.63			3.73			3.35

The diluted net earnings per share calculation includes the dilutive effect of convertible debt: a decrease in interest expense of $4 million, $4 million and $11 million after tax for years 2007, 2006 and 2005, respectively.

Diluted net earnings per share excludes 64 million, 43 million and 45 million shares underlying stock options for 2007, 2006 and 2005, respectively, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share.

20. Capital and Treasury Stock

Changes in treasury stock were:


(Amounts in Millions Except Treasury Stock	Treasury Stock
Number of Shares in Thousands)	Shares			Amount

Balance at January 2, 2005		148,819		$	6,004
Employee compensation and stock option plans		(22,708	)		(1,458	)
Conversion of subordinated debentures		(7,976	)		(501	)
Repurchase of common stock		27,229			1,920

Balance at January 1, 2006		145,364			5,965
Employee compensation and stock option plans		(26,526	)		(1,677	)
Conversion of subordinated debentures		(540	)		(36	)
Repurchase of common stock		108,314			6,722

Balance at December 31, 2006		226,612			10,974
Employee compensation and stock option plans		(33,296	)		(2,180	)
Conversion of subordinated debentures		(194	)		(13	)
Repurchase of common stock		86,498			5,607

Balance at December 30, 2007		279,620		$	14,388

Aggregate shares of Common Stock issued were approximately 3,120 million shares at the end of 2007, 2006 and 2005.

Cash dividends paid were $1.620 per share in 2007, compared with dividends of $1.455 per share in 2006, and $1.275 per share in 2005.



72		JOHNSON & JOHNSON 2007 ANNUAL REPORT

21. Selected Quarterly Financial Data (unaudited)

Selected unaudited quarterly financial data for the years 2007 and 2006 are summarized below:


	2007											2006
	First			Second		Third			Fourth			First			Second			Third			Fourth
(Dollars in Millions Except Per Share Data)	Quarter		⁽¹⁾	Quarter		Quarter		⁽²⁾	Quarter		⁽³⁾	Quarter		⁽⁴⁾	Quarter		⁽⁵⁾	Quarter		⁽⁶⁾	Quarter		⁽⁷⁾

Segment sales to customers
Consumer	$	3,496			3,564		3,623			3,810			2,355			2,398			2,456			2,565
Pharmaceutical		6,221			6,149		6,099			6,397			5,626			5,810			5,881			5,950
Med Devices & Diagnostics		5,320			5,418		5,248			5,750			5,011			5,155			4,950			5,167

Total sales	$	15,037			15,131		14,970			15,957			12,992			13,363			13,287			13,682

Gross profit		10,652			10,773		10,696			11,223			9,380			9,575			9,637			9,675
Earnings before provision for taxes on income		3,652			4,031		3,268			2,332			4,615			3,603			3,661			2,708
Net earnings		2,573			3,081		2,548			2,374			3,305			2,820			2,760			2,168

Basic net earnings per share	$	0.89			1.06		0.88			0.83			1.11			0.96			0.95			0.75

Diluted net earnings per share	$	0.88			1.05		0.88			0.82			1.10			0.95			0.94			0.74


⁽¹⁾		The first quarter of 2007 includes an after-tax charge of $807 million for IPR&D.

⁽²⁾		The third quarter of 2007 includes an after-tax charge of $528 million for restructuring.

⁽³⁾		The fourth quarter of 2007 includes an after-tax charge of $441 million for the NATRECOR^® intangible asset write-down and a one-time tax gain of $267 million for restructuring. The low tax rate is due to increases in taxable income in lower tax jurisdictions relative to taxable income in higher tax jurisdictions.

⁽⁴⁾		The first quarter of 2006 includes an after-tax gain of $368 million for the Guidant acquisition termination fee and an after-tax charge of $29 million for IPR&D.

⁽⁵⁾		The second quarter of 2006 includes an after-tax charge of $87 million for IPR&D.

⁽⁶⁾		The third quarter of 2006 includes an after-tax charge of $115 million for IPR&D.

⁽⁷⁾		The fourth quarter of 2006 includes an after-tax charge of $217 million for IPR&D.

22. Restructuring

In the third quarter of 2007, the Company announced restructuring initiatives in an effort to improve its overall cost structure. This action was taken to offset the anticipated negative impacts associated with generic competition in the Pharmaceutical segment and challenges in the drug-eluting stent market. The Company’s Pharmaceuticals segment will reduce its cost base by consolidating certain operations, while continuing to invest in recently launched products and its late-stage pipeline of new products. The Cordis franchise is moving to a more integrated business model to address the market changes underway with drug-eluting stents and to better serve the broad spectrum of its patients’ cardiovascular needs, while reducing its cost base. This program will allow the Company to accelerate steps to standardize and streamline certain aspects of its enterprise-wide functions such as human resources, finance and information technology to support growth across the business, while also leveraging its scale more effectively in areas such as procurement to benefit its operating companies. Additionally, as part of this program the Company plans to eliminate approximately 4,400 positions of which approximately 1,400 were eliminated in 2007.

During the fiscal third quarter of 2007, the Company recorded $745 million in related pre-tax charges of which, approximately $500 million of the pre-tax restructuring charges are expected to require cash payments. The $745 million of restructuring charges consists of severance costs of $450 million, asset write-offs of $272 million and $23 million related to leasehold obligations. The $272 million of asset write-offs relate to property, plant and equipment of $166 million, intangible assets of $48 million and other assets of $58 million.

The following table summarizes the severance charges and the associated spending for the fiscal year ended 2007:


(Dollars in Millions)	Severance

2007 severance charge	$	450
Cash outlays*		(46	)
Reserve balance, December 30, 2007	$	404


*		Cash outlays for severance are expected to be paid out over the next 12 to 18 months in accordance with the Company’s plans and local laws.

For additional information on the restructuring as it relates to the segments see Note 11.



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS		73

Management’s Report on Internal Control Over Financial Reporting

Under Section 404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company’s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company’s internal control over financial reporting is effective.

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company’s financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles.

Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management has assessed the effectiveness of the Company’s internal control over financial reporting as of December 30, 2007. In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control-Integrated Framework.” These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. The Company’s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.

Based on the Company’s processes and assessment, as described above, management has concluded that, as of December 30, 2007, the Company’s internal control over financial reporting was effective.

The effectiveness of the Company’s internal control over financial reporting as of December 30, 2007 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.


William C. Weldon Chairman, Board of Directors, and Chief Executive Officer		Dominic J. Caruso Vice President, Finance, and Chief Financial Officer



74		JOHNSON & JOHNSON 2007 ANNUAL REPORT

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Johnson & Johnson:

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of earnings, statements of equity, and statements of cash flows present fairly, in all material respects, the financial position of Johnson & Johnson and its subsidiaries (“the Company”) at December 30, 2007 and December 31, 2006, and the results of their operations and their cash flows for each of the three years in the period ended December 30, 2007 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 30, 2007, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying, “Management’s Report on Internal Control over Financial Reporting.” Our responsibility is to express opinions on these financial statements and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

New York, New York
February 20, 2008



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM		75

Summary of Operations and Statistical Data 1997-2007



(Dollars in Millions Except Per Share Figures)	2007			2006			2005			2004			2003			2002			2001			2000			1999			1998			1997

Sales to customer — U.S.	$	32,444			29,775			28,377			27,770			25,274			22,455			19,825			17,316			15,532			12,901			11,814
Sales to customer — International		28,651			23,549			22,137			19,578			16,588			13,843			12,492			11,856			11,825			10,910			10,708

Total sales		61,095			53,324			50,514			47,348			41,862			36,298			32,317			29,172			27,357			23,811			22,522

Cost of products sold		17,751			15,057			14,010			13,474			12,231			10,498			9,622			8,987			8,559			7,711			7,355
Selling, marketing and administrative expenses		20,451			17,433			17,211			16,174			14,463			12,520			11,510			10,675			10,182			8,595			8,215
Research expense		7,680			7,125			6,462			5,344			4,834			4,094			3,704			3,186			2,821			2,538			2,386
Purchased in-process research and development		807			559			362			18			918			189			105			66			—			298			108
Interest income		(452	)		(829	)		(487	)		(195	)		(177	)		(256	)		(456	)		(429	)		(266	)		(302	)		(263	)
Interest expense, net of portion capitalized		296			63			54			187			207			160			153			204			255			186			179
Other (income) expense, net⁽⁴⁾		534			(671	)		(214	)		15			(385	)		294			185			(94	)		119			12			248
Restructuring		745			—			—			—			—			—			—			—			—			553

		47,812			38,737			37,398			35,017			32,091			27,499			24,823			22,595			21,670			19,591			18,228

Earnings before provision for taxes on income		13,283			14,587			13,116			12,331			9,771			8,799			7,494			6,577			5,687			4,220			4,294
Provision for taxes on income		2,707			3,534			3,056			4,151			2,923			2,522			2,089			1,813			1,554			1,196			1,224

Net earnings		10,576			11,053			10,060			8,180			6,848			6,277			5,405			4,764			4,133			3,024			3,070

Percent of sales to customers		17.3			20.7			19.9			17.3			16.4			17.3			16.7			16.3			15.1			12.7			13.6
Diluted net earnings per share of common stock	$	3.63			3.73			3.35			2.74			2.29			2.06			1.75			1.55			1.34			1.00			1.01
Percent return on average shareholders’ equity		25.6			28.3			28.2			27.3			27.1			26.4			24.0			25.3			26.0			21.6			24.3

Percent increase over previous year:
Sales to customers		14.6			5.6			6.7			13.1			15.3			12.3			10.8			6.6			14.9			5.7			5.3
Diluted net earnings per share		(2.7	)		11.3			22.3			19.7			11.2			17.7			12.9			15.7			34.0			(1.0	)		4.1

Supplementary expense data:
Cost of materials and services⁽¹⁾	$	27,967			22,912			22,328			21,053			18,568			16,540			15,333			14,113			13,922			11,779			11,702
Total employment costs		14,571			13,444			12,364			11,581			10,542			8,942			8,153			7,376			6,727			6,021			5,634
Depreciation and amortization		2,777			2,177			2,093			2,124			1,869			1,662			1,605			1,592			1,510			1,335			1,117
Maintenance and repairs⁽²⁾		483			506			510			462			395			360			372			327			322			286			270
Total tax expense⁽³⁾		4,177			4,857			4,285			5,215			3,890			3,325			2,854			2,517			2,221			1,845			1,811

Supplementary balance sheet data:
Property, plant and equipment, net		14,185			13,044			10,830			10,436			9,846			8,710			7,719			7,409			7,155			6,767			6,204
Additions to property, plant and equipment		2,942			2,666			2,632			2,175			2,262			2,099			1,731			1,689			1,822			1,610			1,454
Total assets		80,954			70,556			58,864			54,039			48,858			40,984			38,771			34,435			31,163			29,019			23,634
Long-term debt		7,074			2,014			2,017			2,565			2,955			2,022			2,217			3,163			3,429			2,652			2,084
Operating cash flow		15,249			14,248			11,799			11,089			10,571			8,135			8,781			6,889			5,913			5,104			4,209

Common stock information
Dividends paid per share	$	1.620			1.455			1.275			1.095			0.925			0.795			0.700			0.620			0.550			0.490			0.425
Shareholders’ equity per share	$	15.25			13.59			13.01			10.95			9.25			7.79			8.05			6.82			5.73			4.95			4.52
Market price per share (year-end close)	$	67.38			66.02			60.10			63.42			50.62			53.11			59.86			52.53			46.63			41.94			32.44
Average shares outstanding (millions) — basic		2,882.9			2,936.4			2,973.9			2,968.4			2,968.1			2,998.3			3,033.8			2,993.5			2,978.2			2,973.6			2,951.9
— diluted		2,910.7			2,961.0			3,002.8			2,992.7			2,995.1			3,049.1			3,089.3			3,075.2			3,090.4			3,067.0			3,050.0

Employees (thousands)		119.2			122.2			115.6			109.9			110.6			108.3			101.8			100.9			99.8			96.1			92.6


⁽¹⁾		Net of interest and other income.

⁽²⁾		Also included in cost of materials and services category.

⁽³⁾		Includes taxes on income, payroll, property and other business taxes.

⁽⁴⁾		2007 includes a $678 million before tax write-down related to the NATRECOR^® intangible asset.



76		SUMMARY OF OPERATIONS AND STATISTICAL DATA

Shareholder Return Performance Graphs

Set forth below are line graphs comparing the cumulative total shareholder return on the Company’s Common Stock for periods of five years and ten years ending December 31, 2007, against the cumulative total return of the Standard & Poor’s 500 Stock Index, the Standard & Poor’s Pharmaceutical Index and the Standard & Poor’s Health Care Equipment Index. The graphs and tables assume that $100 was invested on December 31, 2002 and December 31,1997 in each the Company’s Common Stock, the Standard & Poor’s 500 Stock Index, the Standard & Poor’s Pharmaceutical Index and the Standard & Poor’s Health Care Equipment Index and that all dividends were reinvested.



	2002		2003		2004		2005		2006		2007
Johnson & Johnson	$	100.00		97.90		122.57		118.40		133.09		137.88
S&P 500 Index	$	100.00		128.70		142.73		149.72		173.38		182.91
S&P Pharmaceutical Index	$	100.00		108.80		100.75		97.32		112.80		118.10
S&P Health Care Equipment Index	$	100.00		132.00		148.63		148.78		154.88		162.78



	1997		1998		1999		2000		2001		2002		2003		2004		2005		2006		2007
Johnson & Johnson	$	100.00		129.00		145.13		165.73		188.94		174.01		170.36		213.28		206.03		231.58		239.92
S&P 500 Index	$	100.00		128.60		155.61		141.45		124.61		97.07		124.93		138.55		145.34		168.31		177.56
S&P Pharmaceutical Index	$	100.00		149.00		131.12		178.59		152.69		122.15		132.90		123.07		118.88		137.79		144.26
S&P Health Care Equipment Index	$	100.00		141.60		130.56		191.39		181.63		158.75		209.55		235.95		236.18		245.87		258.41



SHAREHOLDER RETURN PERFORMANCE GRAPHS		77


MANAGEMENT’S DISCUSSION AND ANALYSIS
36		Organization and Business Segments
36		Results of Operations
37		Analysis of Sales by Business Segments
40		Analysis of Consolidated Earnings Before Provision for Taxes on Income
42		Liquidity and Capital Resources
44		Other Information
47		Cautionary Factors That May Affect Future Results

AUDITED CONSOLIDATED FINANCIAL STATEMENTS
48		Consolidated Balance Sheets
49		Consolidated Statements of Earnings
50		Consolidated Statements of Equity
51		Consolidated Statements of Cash Flows
52		Notes to Consolidated Financial Statements
74		Management’s Report on Internal Control over Financial Reporting
75		Report of Independent Registered Public Accounting Firm
76		Summary of Operations and Statistical Data 1997–2007
77		Shareholder Return Performance Graphs


Consolidated Statements of Earnings		Johnson & Johnson and Subsidiaries